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ABSTRACT
We present here the first update of the 2013 EFSUMB (Euro-
pean Federation of Societies for Ultrasound in Medicine and
Biology) Guidelines and Recommendations on the clinical use
of elastography, focused on the assessment of diffuse liver dis-
ease. The first part (long version) of these Guidelines and Re-
commendations deals with the basic principles of elastogra-
phy and provides an update of how the technology has
changed. The practical advantages and disadvantages asso-
ciated with each of the techniques are described, and gui-
dance is provided regarding optimization of scanning tech-
nique, image display, image interpretation, reporting of data
and some of the known image artefacts. The second part pro-
vides clinical information about the practical use of elastogra-
phy equipment and the interpretation of results in the assess-
ment of diffuse liver disease and analyzes the main findings
based on published studies, stressing the evidence from
meta-analyses. The role of elastography in different etiologies
of liver disease and in several clinical scenarios is also discus-
sed. All of the recommendations are judged with regard to
their evidence-based strength according to the Oxford Centre
for Evidence-Based Medicine Levels of Evidence. This updated
document is intended to act as a reference and to provide a
practical guide for both beginners and advanced clinical
users.
ZUSAMMENFASSUNG
Dies ist die erste Überarbeitung der 2013 publizierten EF-
SUMB-Leitlinien zur klinischen Anwendung der Elastographie
und konzentriert sich auf die diffusen Lebererkrankungen.
Der erste Teil dieser Leitlinien und Empfehlungen handelt
von den Grundlagen der Elastografie und erläutert die Weiter-
entwicklungen der Technologie während dieses Zeitraumes.
Die praktischen Vor- und Nachteile der verschiedenen Techni-
ken werden beschrieben. Auch die Optimierung der Untersu-
chungstechnik, Bilddarstellung, Bildinterpretation und die
Befundbeschreibung sowie Artefakte werden dargelegt. Der
klinische Teil dieser Leitlinien erläutert die praktische Anwen-
dung der Elastografie bei der Beurteilung diffuser Lebererk-
rankungen unter Berücksichtigung der Geräteausstattung
und Interpretation der Ergebnisse. Die aktuelle Literatur
wurde analysiert unter besonderer Beachtung von Metaanaly-
sen. Die klinische Anwendung der Elastografie wird unter
Reflexion unterschiedlicher klinischer Szenarien und der
unterschiedlichen Ätiologien diffuser Lebererkrankungen
erläutert. Alle Empfehlungen erfolgten gemäß der Evidenz
basierten Methodik der Oxford-Klassifikation. Das hier vorges-
tellte Update soll dem Anfänger und fortgeschrittenen Nutzer
eine praktische Hilfe darstellen.
Basic Principles and Technology
Introduction
In these guidelines, the term elastogram refers to any image of
any elastic property of tissue. This article also describes non-imag-
ing measurements of such characteristics over a defined region.
These are referred to as point elastography methods. Elastometry,
on the other hand, is the measurement of an elastic characteristic
of tissue, which may be obtained from either imaging or non-
imaging methods.
The basic principles of elastography have not changed since
they were outlined in the first part of the original EFSUMB guide-
lines and WFUMB guidelines on this subject [1, 2]. This paper
therefore aims to provide an update of technology changes as of
2017 in this rapidly evolving field. Sufficient recapitulations are
provided to allow the present paper to be understood without
reference to the earlier paper, although the purpose is not to
reproduce the material of the 2013 paper in detail.
Basic principles of elastography
We recommend that elastography be considered as a type of
remote palpation that allows measurement and display of biome-
chanical properties associated with the elastic restoring forces
in the tissue that act against shear deformation. This view unifies
the different types of elastography and explains why they all
display images with contrast to obtain the same underlying infor-
mation, associated with the shear elastic modulus defined below.
It is explained in detail in [1], along with different types of shear
deformation. Shear deformation is generated by a force applied
to a single location or broadly across the body surface. Important-
ly, transient shear deformations will propagate as shear waves,
as discussed below.
A force may be applied by pressing on or vibrating the body
surface, by naturally occurring internal physiological motion
or by electronically controlling the ultrasound transducer to
create focused acoustic radiation force at a controlled depth. The
acoustic radiation force is: proportional to the time-averaged
intensity I of the sound beam at the push location and the ampli-
tude absorption coefficient α at the push location, inversely
proportional to the speed of sound cι at the push location and
increases with any reflection or scattering of the sound at the
push location. In the absence of reflection or scattering, the
magnitude of the radiation force acting at each point in the
volume of the medium is F = 2αI / cι [3]. All ultrasound beams gen-
erate such force but the force integrated over the length of a
e17Dietrich CF et al. EFSUMB Guidelines and… Ultraschall in Med 2017; 38: e16–e47
D
ow
nl
oa
de
d 
by
: U
ni
ve
rs
ità
 L
a 
Sa
pi
en
za
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
diagnostic pulse (< 2 μs) is too small to generate a measurable
displacement. Beams designed to create a measurable displace-
ment with acoustic radiation force use deliberately longer pulses
(50 – 1000 μs) to generate micron-level tissue displacements.
All available ultrasound elastography methods (▶ Fig. 1) em-
ploy ultrasound to measure the internal tissue shear deformations
resulting from an applied force. The type of force (▶ Fig. 1, col-
umn 2) is important. If the force varies slowly relative to the shear
propagation time to the depth of interest, as is the case for probe
palpation or physiological motion, it is considered quasi-static.
It is difficult to acquire images that are quantitative for tissue
properties using a quasi-static applied force although quantifica-
tion relative to a reference tissue or phantom material may be
possible. Dynamic forces permit absolute quantification of tissue
property. They include impulses and continuous vibrations, and
may be produced mechanically at the body surface or deep within
the body using acoustic radiation force. Only impulsive dynamic
forces are shown in ▶ Fig. 1 because current commercial ultra-
sound elastography systems still do not use a continuously vibrat-
ing force, although there are examples of this in the research
reported in the ultrasound elastography literature [4 – 6]. This is
unlike magnetic resonance elastography (MRE), where a continu-
ous harmonic vibration induced at the body surface is the most
common approach [7 – 9].
The signal processing within the scanner for all current com-
mercial ultrasound elastography methods begins with the meas-
urement of tissue displacement as a function of spatial position
and time, which is done using cross-correlation tracking, Doppler,
or other signal processing. The various elastography methods
differ with respect to what they do with these displacement
data to create an elastogram or elasticity measurement. There
are three options for the property to be displayed (▶ Fig. 1,
column 4):
a) Display of displacement without further processing (▶ Fig. 1,
row 2), as in acoustic radiation force impulse (ARFI) imaging.
Tissue displacement is associated with shear deformation.
The greater the force, the greater the displacement, but stiff
tissues are displaced less than soft tissues. Stiffness is defined
as applied force divided by the generated tissue displacement.
If the force (not normally known) is assumed to be the same for
all image locations, an image of displacement can be thought
of as an inverse relative stiffness map (it is the inverse, because
the stiffer the tissue, the smaller the displacement). Note that
stiffness is not only governed by the tissue’s mechanical prop-
erties but is also governed by geometrical factors such as the
area of the cross-section of the tissue sample over which the
force is applied. Although displacement itself is a quantitative
measurement (units of μm), image brightness is typically
scaled between soft (bright) and hard (dark).
b) Display of tissue strain or strain rate (▶ Fig. 1, row 1), calculat-
ed from the spatial gradient of displacement or velocity,
respectively, as in strain elastography (SE).
Displacement imaging works well when a highly localized force
is applied internally at a depth, as in ARFI imaging. However,
when the force is applied across a large region of the surface
of the body, strain provides a better measure of deformation,
as, unlike displacement, it does not decay with depth. Young’s
modulus E is a true tissue property, measurable by axial com-
pression of a tissue sample with a constant cross-sectional area
along its length. It is equal to the applied stress σ divided by
the measured strain ε, i. e., the well-known Hooke’s law E = σ / ε,
where stress is the applied force per unit area and strain is the
change in length of the sample divided by its original length.
If the stress (not normally known) is assumed to be the same
for all image locations, an image of strain can be thought of as
an inverse relative Young’s modulus map (it is the inverse, be-
cause the higher the Young’s modulus, the smaller the strain).
Although strain itself is a quantitative measurement (units of %),
image brightness is typically scaled between soft (bright) and
hard (dark).
c) Display of shear wave speed (▶ Fig. 1, rows 3 – 7), calculated
by using the time varying displacement data to measure
the arrival time of a shear wave at various locations. All such
methods are grouped under the heading shear wave elasto-
graphy (SWE), and include transient elastography (TE), point
shear wave elastography (pSWE) and multidimensional shear
wave elastography (2D‑SWE and 3D-SWE).
This is only possible when the force is applied dynamically.
The shear deformation generated locally and momentarily
within tissue will propagate as a shear wave and, so long as it
is not completely attenuated as it travels, will reach a distant
location after a time determined by the shear wave speed cs.
Shear wave speed may be displayed in units of ms–1. Alterna-
tively, assuming that it does not vary with the magnitude
or frequency of the applied force, or with position and direc-
tion in the tissue, cs may be converted to either Young’s mod-
ulus E or shear modulus G, using the equations E = 3ρcs2 and
G = E / 3 (assuming the tissue is incompressible), where ρ is the
density of the tissue. E and G are expressed in units of kilopas-
cal (kPa). The choice of whether to display speed or modulus
may be under user control, or such a choice may be unavailable
(sometimes determined by regulatory authorities for the re-
gion of the world in which the scanner or measurement system
is manufactured or sold).
Explanation: It is typical of the MRE literature that data are
provided for shear modulus G, whereas in the ultrasound elas-
tography literature it is more common to provide values for
Young’s modulus E. The reader should be wary when compar-
ing data across published papers, as both quantities are
expressed in the same units (kPa), and yet E = 3G. When pub-
lishing results of studies, it is important to state which modu-
lus has been measured when using units of kPa, avoiding
non-specific terms such as stiffness, and to say how it was
calculated.
The reasons why ultrasound can be used to make
elastograms
Ultrasound is the propagation of a transient density deforma-
tion. In soft tissues, it travels at speeds in the range of 1350 –
1600ms–1, whereas shear deformation travels much slower, in
the range of 1 – 10ms–1 [10]. This speed difference means that
ultrasound may be used to measure tissue displacements at pre-
cise phases of shear deformation. Ultrasound also suffers relative-
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▶ Fig. 1 The types of elastography described in this paper.
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ly little attenuation, allowing high-resolution (mm) measure-
ments of displacements of a few microns at depths of many cen-
timeters. Furthermore, the speckle in ultrasound images allows
measurements of tissue displacements even when there are no
resolved tissue structures to track.
The differences between elastograms and
ultrasound images
The tissue contrast in all types of elastograms is potentially very
high because it is related to differences in shear modulus G, which
varies by more than five orders of magnitude across all soft
tissues, as compared with bulk modulus K which varies by about
12%. Ultrasound is able to propagate through fluids, and in tissue
the molecular composition largely determines ultrasound speed
and absorption, whereas shear will not propagate in a non-viscous
pure fluid and is transferred largely via the high-level tissue struc-
ture. Although ultrasound scattering occurs at the large-scale
structural level, it also arises at the cellular level and does not
require the structure to be connected. Shear on the other hand
will not propagate across zero friction breaks in the structural
matrix. For example, a dilute suspension of cells in saline will scat-
ter ultrasound but will not support a shear deformation or a shear
wave. Finally, and very importantly, unlike the situation for ultra-
sound propagation and scattering, the shear modulus of most
tissues increases with vascular and interstitial pressure. These
features may make elastography sensitive to the presence of
disease in situations where conventional ultrasound imaging fails
to detect it.
Technology of ultrasound elastography
The types of elastography referred to above and commercially
available systems are shown in ▶ Fig. 1. Note that they may be
complementary in many respects for general clinical use. For
applications in the liver, methods that display shear wave speed
(SWS) are the most common, followed by displacement imaging
(for lesions in the liver) and finally by strain imaging.
Strain elastography (SE) and strain rate imaging (SRI):
quasi-static strain imaging (▶ Fig. 1, row 1)
Strain elastography, although it remains the most widely imple-
mented elastography method on commercial systems, is the least
used method for the liver. As motion occurs due to either palpa-
tion with the ultrasound probe or to physiological motion, images
of axial displacement between sequentially acquired ultrasound
echo images are calculated using either radiofrequency echo
correlation tracking or Doppler processing (when Doppler proces-
sing is used the method is often called strain rate imaging). A
moving window axial-gradient estimator converts the axial
displacement images to strain images. Little has changed con-
cerning the available systems, artefacts and advantages and
disadvantages of strain imaging, although the trend is towards
increased robustness, using more frame and pixel quality selec-
tion methods, and increased sensitivity allowing useful elasto-
grams to be obtained with little or no palpation, relying on invo-
luntary hand motions or physiological motion, on some systems.
Advice concerning semi-quantitative analysis of strain images
using, for example, strain ratios and strain histograms, remains
as described in [1].
Acoustic radiation force impulse (ARFI) imaging:
imaging tissue displacement induced by radiation
force (▶ Fig. 1, row 2)
The axial displacement for locations down a given image line at
and around a single pushing focus is measured by comparing the
locations of tissue echoes and/or speckle for imaging pulses emit-
ted before and immediately (< 1ms) after the push. A displace-
ment image within a small region of interest (ROI) is then ac-
quired by repeating the pulse sequence “image-push-image” for
a sequence of A-lines in the ROI. ARFI remains the proprietary
imaging technology Siemens Virtual Touch™ as described in
2013, and the advantages and disadvantages and the various im-
age artefacts remain unchanged [1]. It is not used for assessment
of diffuse liver conditions.
Shear wave elastography (SWE); methods that use
shear wave speed
Transient elastography (TE): shear wave elastometry by
measurement of the speed of a shear wave that has been
generated using a surface impulse (▶ Fig. 1, row 3)
Despite the name, this is not the only method that uses a transient
force. All of the dynamic methods in ▶ Fig. 1 do so. This device is
designed only for liver elasticity measurement and for use also by
persons who are not imaging specialists. An automated move-
ment of a piston, which is also a disc-shaped ultrasound transduc-
er, applies a single cycle 50Hz push to the body surface with con-
trolled applied force. The transient shear deformation created in
this way, propagates into the tissue. Its near constant speed for
about 4 cm in the liver (before being rendered non-detectable
due to attenuation) is measured by a straight line automatically
fitted to the displacement M-mode shown on the right in
▶ Fig. 2, obtained by processing the ultrasound radio frequency
A-mode echo signal versus time.
Point shear wave elastography (pSWE): shear wave elasto-
metry at a location by measurement of the speed of a
shear wave generated using acoustic radiation force
(▶ Fig. 1, row 4)
When an ARFI is applied at a depth within tissue, a shear wave is
generated. Its average speed of propagation from the focal point
positioned on one lateral boundary of a measurement ROI to an-
other on the opposite lateral boundary of the ROI may be meas-
ured by detecting its time of arrival at that point, relative to that
of the ARFI. As with TE, no elastograms are created. Only a regio-
nal average of SWS is measured. Ultrasound imaging is used, how-
ever, to guide placement of the ROI, and measurement may be
made even when it is necessary to propagate through ascites.
Other advantages and disadvantages are described in [1]. The
main update since [1] is that, as listed in ▶ Fig. 1, more manufac-
turers are now providing this type of measurement, which was
known as ARFI quantification when first introduced by Siemens.
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Currently, this option is also offered by Esaote, GE, Hitachi, Philips
and Samsung.
The quality of the SWS estimate is judged by the SWS estima-
tion algorithms in pSWE systems and may warn the user if it is not
adequate.
Multidimensional shear wave elastography (2D-SWE, 3D-
SWE): quantitative SWE imaging (and elastometry) by
measuring the speed of shear waves generated using
acoustic radiation force (▶ Fig. 1, rows 5 – 7)
The method described above for pSWE may be extended to make
quantitative images of SWS in a large ROI by placing the ARFI
focus (push) at multiple sequential locations and, at each, detect-
ing the shear wave arrival time at multiple lateral locations. This
creates patches of small SWS images that may be mosaicked to
create a large ROI 2D-SWE image, which is displayed in color or
grayscale. This may be overlaid with adjustable transparency on
the B-mode image or, optionally, the SWE image and B-mode
may be displayed separately, side-by-side. In addition to visual
judgment of such elastograms against a color scale (calibrated in
ms–1 or kPa), they may be quantitatively analyzed using measure-
ment boxes. These ROIs can be placed at desired locations to
obtain statistical quantities such as the mean, standard deviation,
minimum and maximum values of the SWS or Young’s modulus in
kPa (although the minimum is often not useful because of missing
data values). It takes time to push sequentially and measure
at multiple push locations. Therefore, in some implementations,
a static SWE image is created (in about 700ms on the Siemens
S3000™), which may be repeated upon user command, after
allowing time for the transducer to cool. In the SuperSonic Ima-
gine Aixplorer™ ‘real-time’ 2D-SWE images (up to several frames
per second) are created using a combination of an axially swept
push focus, which generates a push line in the SWE image
ROI and a shear wave that should decay less rapidly than that
from a single push focus. The echo images are generated at
thousands of frames per second by using plane transmitted ultra-
sound waves and highly parallel receive beam-forming to allow
detection of shear wave arrival times at many locations without
the need for many repeated ARFI pushes.
The main update since [1] is that other manufacturers, includ-
ing Toshiba, GE, Philips and Mindray, have now released 2D-SWE
products that are broadly similar but differ with respect to the
details of the method and sampling rate.
Toshiba, Philips and Mindray seem to have implemented a
conventional ARFI pushing method similar to Siemens. Mindray
employs highly parallel receive beam-forming and a zoned trans-
mit wave to sample the travelling shear wave at more than 1000
frames per second within areas up to 4 cm wide. Philips also
employs highly parallel processing, allowing free-running 2D-
SWE over areas up to 5 cm high by 7 cm wide with an abdominal
curved array transducer at a frame rate of 0.4 – 1.6Hz, while the
underlying B-mode runs at 20Hz for visual guidance (▶ Fig. 3b).
GE has implemented the “comb push” technique [11], which
(as illustrated in ▶ Fig. 4) pushes along a number of ARFI lines
simultaneously. As a consequence, the propagating shear waves
travelling away from different push lines pass each other. To avoid
confusion of detected times of arrival for waves travelling in differ-
ent directions, the system analyzes the arrival time at a constant
depth as a function of lateral position and uses Fourier domain
filtering to separate waves travelling to the left from those travel-
ling to the right. In combination with time-interleaved interpola-
tion of the displacement tracking results, this allows an accepta-
bly large 2D-SWE ROI to be formed in about 100ms using a
conventional (hardware) beamformer.
Note that direction filtering is also employed by other manu-
facturers, because it has the additional benefit of reducing SWS
measurement artefacts that are, for example, due to shear wave
reflections at shear impedance boundaries (where either the
tissue density or the shear wave speed changes). It is also becom-
ing common on the recent 2-SWE systems (e. g. Toshiba, GE,
Mindray) to provide a choice between a continuously refreshed
image (almost real time) and a more slowly acquired, said to be
of higher quality, single frame.
All 2D-SWE systems have built-in indicators of the quality of
the shear-wave speed estimate and take appropriate action to
adjust the display when the quality falls too low, such as dropping
out the offending pixel of the 2D-SWE image overlay to allow the
▶ Fig. 2 Transient elastography with the Fibroscan™. Sample dis-
play showing the echo M-scan on the left, single-line amplitude A-
scan in the middle, and the displacement M-mode after a vibration-
controlled impulse push on the surface (see [1] for a full explana-
tion).
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B-mode image to show through, or setting that pixel to black.
Typically, this will occur as the signal-to-noise ratio deteriorates
with depth, limiting the penetration capability of 2D-SWE, as in
the example shown in ▶ Fig. 5.
An additional approach to quality judgement is provided by
Toshiba as shown in ▶ Fig. 6 (right), which optionally shows the
detected times of arrival in a “wavefront” style of display. The con-
cept is that if consecutive lines are parallel (even if irregular), the
quality is acceptable, but it would not be acceptable if they are
not parallel. In the image shown, it can be seen that time-of-arri-
val lines become spread further apart when the speed increases
(c.f. image on the left). It appears as if the shear wave has propa-
gated from left to right, becoming irregular in shape as it emerges
on the right of the relatively stiff inclusion, where the elastogram
appears to show a stiffer region in the background but the non-
parallel time-of-arrival lines in the image on the right indicate
that this is an artefact.
Philips provides an additional optional confidence map
(▶ Fig. 3c) that combines multiple image quality metrics, which
may be displayed concurrently with the elastogram, and that
guides the operator with respect to making measurements
(either online or retrospectively on stored images) in areas where
confidence in the SWS assessment is high.
ROIs with a side length of many centimeters may usually be set
and 2D-SWE image penetration depth may be at least 8 cm,
depending on the system and transducer used. Extensions to
make 3D quantitative SWE images (3D-SWE) have to date been
limited to the use of 3D probes that contain mechanically swept
1D transducer arrays. Such a feature is available on the SuperSo-
nic Imagine Aixplorer™, which is able to take advantage of its real-
time 2D-SWE capability to acquire a 3D-SWE image stack.
The majority of advantages, disadvantages and artefacts for
SWE imaging remain as discussed in [1]. Pressure of the probe
may cause superficial tissues to stiffen because of the nonlinear
stress-strain character of tissue, but the resulting high shear
wave speed artefact is generally not a problem for liver imaging
because it only occurs near the surface.
Note that an absence of echo signal on the B-mode image does
not always produce an absence of SWE signal, as should happen in
a cystic structure (e. g. ▶ Fig. 6, left). The artefactual SWE signal
may result from an interaction between the relatively large slice
thickness typical of most SWE images and limited elevational
dimensions of the cystic structure. Similar influences of the back-
ground on quantitative shear wave speed values for any small
structures, whether solid or cystic, stiff or soft, can be expected.
Penetration depth of the various technologies
When SE relies on the application of a quasi-static surface defor-
mation rather than internal physiological motion, the limited
area of the probe (among other factors) causes the strain to decay
rapidly with depth. This limits the use of SE to only the most
superficial regions of the liver, although the use of a probe foot-
print extender may increase the depth over which strain informa-
tion is useful.
For the dynamic deformations employed by the SWE methods,
as with ultrasound waves, the attenuation of shear waves in tissue
increases with frequency, except that the attenuation coefficient
for shear waves is about 1014 times that for ultrasound at the
same frequency [13]. As a result, very low force-vibration fre-
quencies must be used to generate shear waves for elastography.
When surface mechanical sources are used to create the shear
waves (as in TE), shear wave penetrations of many centimeters
are needed, requiring the use of frequencies of tens of Hz. When
▶ Fig. 3 Example of 2D-SWE in the liver as implemented on the Philips EPIQ™ b, which may be displayed concurrently with the B-mode image a and
a confidence map c described in the text.
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focused ARFI is used to create the shear waves, the shear waves
do not need to reach the depth of interest by propagation from
the surface and higher shear wave frequencies (hundreds of Hz)
may be employed because the penetration is achieved by the
ultrasound beam used to generate the shear wave. Even though
the shear wave may then travel only a short distance (because of
its higher frequency), another shear wave may easily be gener-
ated at a new source position using another ARFI beam.
Although the wavelength is about a thousand times shorter
for shear waves than for ultrasound waves of the same frequency,
the fact that the frequencies are so low for SWE means that
wavelengths are in the region of many centimeters (wave-
length = speed divided by frequency). Shear wave sources such as
surface thumpers or focused acoustic radiation force impulses are
typically therefore smaller than a wavelength, producing diverg-
ing shear waves. Nevertheless, the method described above for
ultrasonically sweeping the ARFI focus faster than the SWS, which
has been used to create a line-like source deep in the tissue, could
be used to create a source that is to some extent focused.
kPa or m s–1?
As mentioned in 1.2c) some SWE systems allow a choice for the
image scale and the measurements to be reported in units of
either ms–1 or kPa. There is more than one reason why it is prefer-
able to report results in units of ms–1 rather than kPa. First, this is
the unit of shear wave speed cs, which is the quantity measured by
the scanner. If the user requests the results in kPa, the unit of
elastic modulus, the scanner must convert the measured data to
an elastic modulus, such as Young’s modulus E. This conversion
typically makes use of a very simple equation, E = 3ρcs2. As with
most simple equations, many assumptions are made and these
are generally not valid. In this case, these assumptions include
that:
a) The tissue density is always 1000 kg m–3. This may not always
be true, although the error resulting from the assumption may
be small.
b) There is no variation of the elastic modulus with the magnitude
of applied force (i. e., either the push magnitude that gener-
ates the shear wave or any pre-stress, such as probe pressure
or portal hypertension, upon which the push is superimposed).
This is equivalent to assuming that the tissue’s elastic response
is linear. In general, this is not true and indeed, in the future it is
expected that the amount of non-linearity will be found to be
an important tissue property.
c) There is no variation of the elastic modulus with the shear wave
frequency. This is equivalent to assuming that the tissue is
purely elastic, although in fact all tissues are viscoelastic, caus-
ing the tissue to become stiffer the faster it is strained, i. e., the
higher the frequency.
d) There is no variation of the elastic modulus with direction, i. e.,
the tissue is mechanically isotropic, although almost all tissues
are on some length scale anisotropic.
e) There are no tissue boundaries or structures nearby which may
cause the wave to travel as another kind of wave (e. g., a Lamb
or Rayleigh wave), or shear wave scatterers, all of which will
invalidate the assumed relationship between speed and elastic
modulus.
▶ Fig. 4 The comb push technique in the GE LOGIQ E9™, which includes shear wave directional filtering for SWE using a conventional (hardware)
beam former [12].
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The fact that these assumptions may not be correct for many
tissues makes the elastic modulus an indirect measurement.
Accurate conversion of measured speed to Young’s modulus
requires much more complex equations and many more measure-
ments, and is in general impossible. Shear wave speed is the direct
measurement, and the U.S. Food and Drug Administration has
thus far only approved systems for sale that use numerical elasto-
graphy displays in units of SWS.
Second, tissue elastic modulus values in the literature are often
given for G, the shear modulus, rather than Young’s modulus. In
particular, this is the convention in the MRE literature. Both mod-
uli have units of kPa, which may mislead into thinking that data
can be pooled, whereas the numerical values for the two moduli
are different. Conversion using the relation E = 3G is possible,
under the assumption that the tissue is incompressible, but to
apply this relationship authors must state which modulus has
been measured.
Reporting results in terms of SWS (ms–1) would appear to re-
solve these difficulties. However, it does not free the scientist
from having to provide full details of all of the above experimental
variables (a-e), particularly the shear wave frequency, since the
SWS will vary with each of them.
Finally, although it is advisable to report SWS rather than
elastic modulus, there are complexities. First, measurements of
viscoelasticity are likely to be provided on ultrasound elastography
systems. This is already the case for MRE, where results are often
cited in the form of a complex shear modulus with real and
imaginary components. This means that the situation for ultra-
sound elastography will have to be kept under review, although a
preferred method (rather than in the future switching to an indir-
ect measurement such as the complex shear modulus) may be to
report direct measurements such as SWS and shear wave attenua-
tion coefficient, and their frequency dependences. It is important
to realize that because of the squared relationship between mod-
ulus and speed, means and standard deviations calculated for
data recorded in ms–1 and then converted to kPa will not be equal
to the means and standard deviations calculated after first con-
verting the original data values to kPa. This will be true across
patient datasets and for means and standard deviations calculat-
ed over ROIs for inhomogeneous tissues. Consideration of this
issue is essential when trying to pool data.
Comparability of data between the different SWE
technologies
As already indicated, measured values of SWS will vary with a
number of system factors, in particular shear wave vibration
frequency and bandwidth. In addition, measurement bias may
occur due to the software method employed, for example, to
calculate relative shear wave arrival time and speed. Thus,
although it is always a good idea to report as many of the experi-
mental and system variables as possible, at present, corrections
for the effects of these variables is not possible. Therefore, unless
▶ Fig. 5 Example of side-by-side display of B-mode (left) and SWE image (right), from a phantom containing a spherical inclusion that has little or
no echo contrast against the background but is softer than the background, illustrating that SWE pixel dropout as poor signal-to-noise ratio at a
large depth reduces the quality of the shear wave speed estimate below that regarded as acceptable, thus limiting the SWE penetration depth.
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a specific study is undertaken to derive an experimental factor in
the subject population of interest, to correct for the biases of
different equipment, data should not be pooled when acquired
using more than one product. Importantly, stiffness thresholds
for clinical use known for specific equipment should not be
utilized for other equipment. Unless proven otherwise, this
recommendation should be taken to apply not only to equipment
from different manufacturers but even to different equipment
from the same manufacturer or different settings for the same
equipment. For example, depth-dependent biases in SWS meas-
urement have been reported. Thus, depth setting standardization
should be employed when accumulating data within a population.
Investigator education
EFSUMB is working to promote high quality in ultrasound educa-
tion and sustain excellent professional standards in elastography
training and practice [14]. To ensure the lowest possible intrao-
perator variability, EFSUMB recommends that ultrasound elasto-
graphy be performed by operators that have passed competence
Level 1. However, it may also be possible to train dedicated
personnel to perform elastographic measurements only [15]. It is
known from TE [16, 17] that the required learning period is short
and this has also been observed in studies using ultrasound
elastography [18, 19]. Nevertheless, it appears that experience in
liver ultrasonography plays a role in the ability to perform stiffness
measurements, at least by means of shear wave imaging, and
leads to more reliable elastographic measurements, particularly
in obese subjects [20].
Operator experience significantly influences the reliability of
liver stiffness measurement (LSM) performed with TE, with an
operator with less than 500 procedures representing a risk of
2.6 fold for unreliable results [21, 22]. TE can be readily learned
by a nurse or a technician after approximately 100 examinations
[16, 17]. 100 examinations should be considered the minimum
required training, and training including > 500 examinations
yields an experienced TE operator.
There is no agreement as to what constitutes an experienced
operator for pSWE and 2D-SWE. Proposed definitions for 2D-SWE
include having performed > 300 abdominal ultrasound scans
or > 50 supervised 2D-SWE examinations [20, 23].
A major question remains: Who should be allowed to acquire
and interpret elastography data? To date, there is insufficient
data in the literature to answer this question adequately.
However, TE acquisition can be performed by nurses or dedicated
persons. Training for non-clinicians should insist on reporting
standards. Interpretation should be performed by a physician
with knowledge of the clinical condition of the patient. The key
issue is to obtain adequate competence and training and to
perform elastography in accordance with the medico-legal regu-
lations of the relevant country. The following recommendations
are in accordance with the EASL guidelines.
The basic principles and technology for elastography were
developed by the academic research community before commer-
cial translation, and it remains a heavily researched and rapidly
developing field. EFSUMB recommends that users maintain an
awareness of this field.
RECOMMENDATION 1
The operator must acquire appropriate knowledge and train-
ing in ultrasound elastography (LoE 5, GoR C). Strong consen-
sus (13/0/0, 100%)
RECOMMENDATION 2
Data acquisition should be undertaken by dedicated and spe-
cially trained personnel. For pSWE and 2D-SWE, experience in
B-mode ultrasound is mandatory (LoE 5, GoR C). Strong con-
sensus (13/0/0, 100%)
▶ Fig. 6 Illustration of the SWE color overlay (left) and “wavefront” style display of detected shear wave time of arrival (right) on the Toshiba Aplio
500™ displaying artefacts. A biopsy training phantom containing cyst-mimicking inclusions that are echo-free but solid and slightly stiffer than the
background was used.
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Shear wave elastography (TE, pSWE and
2D-SWE), general technical comments
Introduction
The liver is an important target organ for the use of elastography;
stiffness correlates with the degree of fibrosis and indirectly with
portal hypertension (see liver application).
Examination procedure
Subjects should be examined in a supine position with the right
arm in maximal extension. The transducer is positioned in a right
intercostal space to visualize the right liver lobe in A or B mode.
Artifacts and large vessels on the A-mode (TE) or B-mode image
(pSWE and 2D-SWE) should be avoided. Optimal measurement
quality of pSWE and 2D-SWE occurs with the ROI placed a mini-
mum of 1 – 2 cm and a maximum of 6 cm beneath the liver cap-
sule [24 – 27]. In the authors’ opinion, the focus should be placed
at the level of the ROI.
Deep inspiration affects the measurement. A transient breath
hold in a neutral position is optimal. Details of the examination
techniques are documented in the specific sections. Measure-
ments in the left liver lobe are significantly higher and show
more variability than those in the right lobe [28, 29]. 2D-SWE
LSMs correlate best with the stage of liver fibrosis when obtained
in the upper right lobe of the liver [30]. LSM in the left liver lobe
should be avoided. The time required for the measurement with
TE, pSWE and 2D-SWE is usually < 5 minutes [31].
RECOMMENDATION 3
Measurement of liver stiffness by SWE should be performed
through a right intercostal space in supine position, with the
right arm in extension, during breath hold, avoiding deep
inspiration prior to the breath hold (LoE 2b, GoR B) [1, 32].
Strong consensus (18/0/0, 100%)
RECOMMENDATION 4
Measurement of liver stiffness by SWE should be performed
by experienced operators (LoE 2b, GoR B) [1, 32]. Strong
consensus (18/0/0, 100%)
RECOMMENDATION 5
Measurement of liver stiffness by pSWE and 2D-SWE should
be performed at least 10mm below the liver capsule (LoE 1b,
GoR A) [24 – 27, 32 – 35]. Strong consensus (18/0/0, 100%)
Fasting and resting
Food ingestion increases measurement readings (independent
of fibrosis) for an estimated 120 – 180 minutes after the meal
[36 – 38]. Moreover, food intake significantly increases the medi-
an interquartile range (IQR) values at 30min and 120min com-
pared with the baseline IQR [39]. It can cause misclassification of
subjects by overestimating the stage of fibrosis, as reported in
subjects infected with the hepatitis C virus (HCV). It may even re-
sult in overstaging of subjects as pre-cirrhotic or cirrhotic, with a
normal fasting value being confirmed by liver biopsy. There are re-
ports that the measurement decreases to true values about 180
minutes after eating [36]. The examination should ideally be per-
formed after an overnight fast, while abstaining from food/drinks
(especially caffeine) and smoking. In addition, since exercise in-
creases liver stiffness, subjects should be examined after a mini-
mum of 10 – 20 minutes of rest [40].
RECOMMENDATION 6
Patients should fast for a minimum of 2 hours and rest for a
minimum of 10 minutes before undergoing liver stiffness
measurement with SWE (LoE 2b, GoR B) [1]. Majority consen-
sus (13/2/3, 72%)
Factors influencing liver stiffness independent of
liver fibrosis (confounders)
Liver stiffness does not solely reflect liver fibrosis, but can reflect
many other physiological or pathological conditions. The majority
of these variables have been described in studies addressing TE,
but should be the same for other SWE methods. Liver stiffness is
increased with hepatic inflammation (often but not exclusively
shown by an elevated transaminase level) [41 – 44], obstructive
cholestasis [45] and hepatic congestion [46, 47]. Also acute toxic
hepatitis (phenprocoumon-induced liver failure) increases meas-
urements [48]. For patients with falsely elevated LSMs due to
alcoholic hepatitis, liver stiffness decreases following 1 – 4 weeks
of abstinence [49 – 51]. Other diseases, which cause increased
liver stiffness, independent of liver fibrosis include amyloidosis,
lymphomas and extramedullary hemopoiesis. Presently, it is
uncertain whether hepatic steatosis modulates liver stiffness [52,
53] or does not [54, 55].
RECOMMENDATION 7
The major potential confounding factors (liver inflammation
indicated by AST and/or ALT elevation > 5 times the normal
limits, obstructive cholestasis, liver congestion, acute hepa-
titis and infiltrative liver diseases) should be excluded before
performing LSM with SWE, in order to avoid overestimation
of liver fibrosis (LoE 2b, GoR B), and/or should be considered
when interpreting the SWE results (LoE 1b, GoR B) [41 – 46,
49 – 51, 56 – 59]. Broad consensus (15/0/1, 94%)
Normal values
TE measurements of Young’s modulus in healthy people vary
between 4.4 and 5.5 kPa (95th percentile 6.7 kPa) [60 – 63]. LSMs
are generally higher in men than in women [60, 61] and may be
affected by steatosis [60] but are not influenced by age [62, 63].
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pSWE measurements using Virtual Touch Quantification
(VTQ®) in healthy populations range between 1.01 and 1.59m/s,
but in most studies the range is 1.07– 1.16m/s [28, 29, 33, 34,
64 – 67]. Age has no apparent influence on the SWS assessed by
VTQ® [28, 29, 67]. All but one study [33] similarly found no corre-
lation between gender or body mass index (BMI) and SWS values.
Depth as assessed by the skin-to-liver capsule distance may influ-
ence the SWS values assessed by VTQ® [28]. In healthy children,
the mean SWS obtained in the right liver lobe was 1.07 ± 0.10m/
s in one study [68] and 1.12m/s (range: 0.73 to 1.45m/s) in an-
other[69]. Regarding the influence of age, there are conflicting re-
sults, since one study reports a statistically significant difference
of SWS values obtained in children < 6 years compared to those
obtained in older children, while another study did not find any
difference [68, 69]. A depth of SWS measurements of up to 5 cm
beneath the skin did not influence accuracy [68, 69].
Values obtained with Elastography point quantification
(ElastPQ®) in healthy people are comparable to those obtained
with VTQ® [70 – 72], although in contrast to VTQ® findings, meas-
urements using ElastPQ® were 8% higher in healthy men than in
healthy women [72].
2D-SWE measurements of Young’s modulus using supersonic
shear imaging (SSI) in healthy subjects cover the range 4.5 –
5.5 kPa (95th percentile 6.2 kPa) [73, 74]. Healthy men may have
higher LSMs than healthy women, while BMI and age do not seem
to influence LSM in subjects without liver disease [74].
For all equipment, an SWE measurement within the normal
range, in a subject without other clinical or laboratory evidence
of liver disease, may exclude significant liver fibrosis with a high
degree of certainty.
The current literature has been recently summarized [75].
RECOMMENDATION 8
SWE within the normal range can rule out significant liver
fibrosis when in agreement with the clinical and laboratory
background (LoE 2A, GoR B) [60, 61]. Broad consensus (17/
0/1, 94%)
Transient elastography (TE)
Procedure
Transient elastography uses an ultrasound displacement M-mode
and A-mode image produced by the system. The operator locates
a portion of the liver at least 6 cm thick and free of large vascular
structures. By pressing the acquisition button, the machine
displays the median of the measured Young’s modulus in kPa,
the IQR (the difference between the 75th and the 25th percen-
tile), IQR/median (IQR/M), the value of the current measurement
and, only in the old version of the system, the success rate (the
ratio between valid and total number of acquisitions). The system
displays a result only if the acquisition is valid, since the software
automatically rejects acquisitions without correct vibration shape
or a correct follow-up of the vibration propagation [1, 32, 76].
The new version of the system suggests using the M or the XL
probe in adult subjects based on calculations of the skin-to-liver
capsule distance. For children as well as in adults with a thoracic
circumference ≤ 75 cm, the S probe is recommended, either S1
for a thoracic circumference < 45 cm or S2 for 45 – 75 cm [77].
How to measure?
Following the manufacturer’s recommendation, assessment is
reliable when 10 valid readings and an IQR ≤ 30% of the median
(IQR/M ≤ 30 %) are obtained. The majority of studies have used
these reliability criteria as well as a success rate ≥ 60 %. Areas
under the receiver operator characteristics (AUROCs) curves
were compared for the prediction of cirrhosis between the
median values of the 3 first, the 5 first and the 10 first successful
acquisitions of TE [78]. No significant loss in performance was
reported if only 5 valid acquisitions were obtained. It is likely that
IQR/M is the key factor for discordance between TE and histologi-
cal fibrosis stage [79, 80]. In a recent large population study, new
reliability criteria based on IQR/M and median LSMs were pro-
posed [81]. According to this study, TE results should be classified
as “very reliable” if IQR/M ≤ 10%, regardless of LSM; “reliable” if
10 % < IQR/M ≤ 30 %, or IQR/M > 30 % with Young’s modulus
< 7.1 kPa and “poorly reliable” if IQR/M > 30% with Young’s mod-
ulus ≥ 7.1 kPa. However, these criteria have not been externally
validated. A reliable TE assessment can be achieved in over 90%
of adults, when both the M and XL probes are used as required
[82 – 85]. Because the M probe takes measurements between 25
and 65mm from the probe, to increase viability, those patients
with a skin-to-liver capsule distance (SCD) of > 25mm should be
assessed with the XL probe. In practice, < 8 % of patients with a
body mass index (BMI) < 30 kg/m2 have an SCD > 25mm. The
rate of SCD > 25mm increases to 50% for patients with a BMI of
35 – 40 kg/m2 [86].
Although the problem of overweight patients is not completely
resolved with the XL probe [85, 87], the applicability of TE increas-
es when both the M and XL probes are available [82– 85, 88– 91].
The diagnostic accuracy of the XL probe appears similar to that of
the M probe but the Young’s modulus values are lower than those
obtained with the M probe by a mean of 1.5 kPa (range of 0.8 –
2.3 kPa) [82 – 85, 92]. The lower values obtained with the XL
probe can be explained by the fact that the validation of the XL
probe in overweight patients was undertaken in comparison with
the M probe. In these patients there is a high probability of SCD
> 25mm and the measurements obtained with the M probe are
likely to be more sub-capsular and, thus, higher [93].
RECOMMENDATION 9
10 measurements should be obtained. An IQR/M ≤ 30% of the
10 measurements is the most important reliability criterion
(LoE 1b, GoR A) [79, 80]. Strong consensus (17/0/0, 100%)
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RECOMMENDATION 10
Values obtained with the XL probe are usually lower than with
the M probe. Therefore, no recommendation on the cut-offs
to be used can be given (LoE 2B, GoR B) [82 – 85, 87]. Broad
consensus (13/1/3, 77%)
Reproducibility
The intra- and interobserver agreements are excellent, with
reported intraclass correlation coefficients (ICC) above 0.90
[94 – 96]. The agreement decreases in overweight patients or in
early stages of fibrosis [94, 95]. Although the LSM seems to be
reproducible at different examination sites, the best examination
site is the median axillary line on the first intercostal space under
the liver percussion dullness upper limit, with the patient lying in
dorsal decubitus [95].
Point shear wave elastography (pSWE)
Experience with point shear wave elastography (pSWE) has been
mainly acquired with the VTQ® product, because it was the first
method available, subsequently followed by ElastPQ® and, more
recently, by pSWE methods from many companies.
Procedure (how to measure?)
The operator can select the depth at which liver elasticity is eval-
uated by placing a “measuring box” (size depending on the man-
ufacturer) in the right liver lobe (segment V, VIII or VII), via an
intercostal approach and with the transducer at 90° in relation to
the liver capsule, in an area free of large vessels. Published studies
[97 – 99] show that reliable measurements can be obtained in
> 90 – 95% of patients. In a pSWE study using VTQ® to measure
SWS [24], the best correlation with histological fibrosis was
observed for measurements performed 1 – 2 cm and 2 – 3 cm
beneath the liver capsule (0.675 and 0.714, respectively), but
in up to 15 % of cases, measurements could not be obtained if
performed 2 – 3 cm under the liver capsule.
RECOMMENDATION 11
Adequate B-mode liver image is a prerequisite for pSWE and
2D-SWE measurements (LoE 5, GoR D). Strong consensus
(18/0/0, 100%)
How many measurements?
Most studies perform 10 valid measurements by pSWE and report
the median of these values. A few studies have used only 5 [99,
100] or 6 [101] valid measurements. Another study [102] calcu-
lated the mean and standard deviation (SD) of 10 valid measure-
ments. A high SD correlated with misclassification of fibrosis.
Additionally, higher stages of fibrosis were associated with a high-
er SD, indirectly indicating that "more" measurements should be
obtained in patients with suspected fibrosis.
RECOMMENDATION 12
The median value of at least 10 measurements should be used
for liver elastography by pSWE (LoE 2b, GoR B) [102] Strong
consensus (18/0/0, 100%)
Reproducibility
pSWE has excellent intra- and inter-operator reproducibility for
liver elastography assessment in both healthy subjects and
patients with chronic liver disease [66, 70, 72, 103 – 105].
Healthy subjects
In a study on SWS measurement, reproducibility was assessed by
VTQ® in 50 healthy volunteers. A very good ICC (0.86) was found
[66]. Age, gender and BMI did not influence the reproducibility
of this method. Similar results (ICC = 0.87) were obtained [103]
in 20 healthy subjects. In a cohort of 69 healthy subjects, ElastPQ®
showed very good intra- (ICC = 0.96) and interobserver
(ICC= 0.93) reproducibility [70].
Patients
The reproducibility of SWS assessed by VTQ® was evaluated in
61 patients with chronic hepatopathies [104]. The following
cut-off values for liver fibrosis staging using SWS were applied:
F≥ 2 – 1.37m/s; F≥ 3 – 1.45m/s and F4 = 1.75m/s. There was 87%
agreement between repeated measurements for different
stages of fibrosis. For the differentiation between patients with
significant fibrosis (F≥ 2 Metavir) and those with fibrosis stage
F< 2, the interoperator agreement was 90 %. In another study
[19] excellent agreement (ICC = 0.84) was observed in a cohort
of 50 patients with various etiologies of chronic liver disease.
Other authors [101] assessed the correlation of SWS values
obtained with VTQ® by 2 operators in 41 patients with chronic
hepatopathies. A good interoperator correlation was obtained
(Spearman correlation coefficient r = 0.874, p < 0.0001) with sim-
ilar results [99, 100, 105]. VTQ® reproducibility for SWS values
and influencing factors were assessed in 33 and 58 patients,
respectively. The overall intraoperator agreement was better
than the interoperator agreement: ICC 0.90 vs. ICC 0.81. For
both intra- and interoperator reproducibility, the ICCs were lower
in women vs. men (0.88 vs. 0.91 and 0.67 vs. 0.86, respectively),
in patients with a high BMI (≥ 25 kg/m²) vs. BMI < 25 kg/m² (0.88
vs. 0.91 and 0.79 vs. 0.82, respectively), in patients with ascites
vs. no ascites (0.80 vs. 0.93 and 0.78 vs. 0.84, respectively) and
in non-cirrhotic vs. cirrhotic patients (0.77 vs. 0.82 and 0.70 vs.
0.83, respectively) [106]. The interobserver reproducibility of the
ElastPQ® technique was assessed in 291 consecutive patients with
chronic hepatitis B (CHB) who underwent partial hepatectomy or
liver biopsy due to hepatocellular carcinoma (HCC). Very good
reproducibility of this technique was achieved (ICC = 0.798) with
a similar conclusion reached in a further study [70].
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Quality criteria
When VTQ® was first introduced, no recommendations regarding
the use of quality criteria for measurements were defined. One
study [107] evaluated factors that influenced the correlation of
SWS assessed by VTQ® with histological fibrosis in a cohort of
106 chronic hepatitis C (CHC) patients. In univariate and multi-
variate analysis, an IQR/M ≥ 30 % was associated with a discor-
dance of at least 2 stages of fibrosis between SWS and histological
fibrosis. The importance of IQR as a quality criterion was further
demonstrated in another study [108]. Others studied the impor-
tance of standard deviation (SD) as a quality criterion [102].
10 valid SWS measurements were adopted in this study and the
mean value was calculated. The authors obtained the following
accuracy for predicting the presence of F≥ 2, F≥ 3 and F = 4 in all
cohorts of patients: 80.7 %, 86.2 % and 88.7 %, respectively. After
the exclusion of patients with SD > 30%, the accuracy of VTQ® for
predicting the same stages of liver fibrosis increased significantly
up to 86.1 %, 91.2 % and 91.5 %, respectively. Using ElastPQ®, a
recent study has suggested that an IQR/M ≤ 30 % is the most
important quality criterion, whereas the number of measure-
ments seems not to affect the performance, provided that they
are at least five [109]. Thus, the compliance with quality criteria
may increase the diagnostic accuracy of pSWE [102, 107]. Quality
parameters have been described for other manufacturers as well
[110].
2D-SWE
Almost all 2D-SWE studies for liver applications have been carried
out using SSI, because other companies have only recently intro-
duced 2D-SWE products. This description is therefore limited
to the SSI system, but the principles may be applied to other
2D-SWE products.
Procedure
Obtaining an elastogram
2D-SWE evaluation should be performed in a well-visualized area
of the right liver lobe, free of large vessels, liver capsule, ligaments
and the gallbladder [30]. Since movement greatly influences
results, the subject is asked to suspend breathing.
With 2D-SWE working in continuous and not with single shot
emissions, the SWE acquisition is continued for 4 – 5 seconds
(can be longer for other scanning systems) once a stable SWE
image is obtained. The operator should aim to achieve homoge-
neous color filling of the SWE ROI. With SSI, the scale of the
elastogram can be modified. Usually a Young’s modulus scale of
up to 30 kPa is sufficient, but a higher scale of up to 150 kPa can
be adopted on a case-by-case basis. The operator freezes the
image (and optionally saves the clip for further post-processing)
and an analysis box (Q Box, for SSI) is placed on the most homo-
geneous, stable elastogram for a few seconds to measure Young’s
modulus (SWS, if the scanner is set to that mode). Experience
seems to play a role in reliable measurement, particularly in obese
patients [20]. However, there is no unified understanding of what
constitutes an experienced 2D-SWE operator. Adequate ultra-
sound knowledge with at least 300 abdominal ultrasound investi-
gations may be considered a minimum requirement [20]. 2D-SWE
measurement of liver elasticity should be performed by experi-
enced operators after achieving a stable, homogeneous elasto-
gram [20, 23].
How to measure?
Analysis box size and shape
For 2D-SWE measurements, the analysis box should be set to at
least 10mm, preferably 15mm or more. A round shape is usually
chosen [57, 58]. The ROI should be placed over an isoechoic area
of liver parenchyma, as seen on the grayscale image (no vessel, no
nodule, no other structure), in priority in the middle line of the
elastogram (avoiding positioning the Q Box on the edges of the
elastogram), while also avoiding SWS artefactual areas (reverbera-
tion, noisy areas from rib shadowing).
Valid and invalid measurements
There is no agreement on objective quality criteria. Some authors
suggest that a minimal Young’s modulus value of ≤ 0.2 kPa in the
analyzed region is useful to identify invalid measurements as
indicated by a lack of concordance with TE [111], while others
use a minimal Young’s modulus < 1 kPa. Furthermore, among
valid measurements an IQR/M ≤ 30 % is recommended by other
studies mimicking TE reliability criteria. The latter criterion, how-
ever, is not supported by evidence. For 2D-SWE with Logiq E9
(GE), the manufacturer recommends an IQR/M value below 30%
as a quality criterion. Temporal stability of the elastogram
for three seconds or more during breath hold, in combination
with placement of the analysis box in a homogeneous area with
complete filling results in high accuracy, high reliability and low
variance of measurements with SSI [112 – 114]. The new software
version of the Aixplorer® system also shows the stability index (SI)
and according to the manufacturer a reliable LSM should exclude
measurements with an SI < 90 %. Aplio 500 (Toshiba) provides a
display of shear waves travelling within the box, allowing selection
of areas not affected by artefacts for analysis. For 2D-SWEwith the
Philips system, a confidence map guides the operator to perform
measurements in areas where the signal-to-noise ratio of the SWS
assessment is high.
Data regarding the best criterion for judging a measurement as
reliable are limited. Hence, following the manufacturer’s advice
for acquisition is suggested in the absence of better evidence
[56, 112 – 114].
How many measurements?
From 3 to 15 measurements are used in published studies, but
data from several studies suggest that 3 measurements suffice
to obtain consistent results for the assessment of liver fibrosis
and portal hypertension, and for optimal correlation with TE [27,
58, 59, 114 – 116]. Some studies report the median, some the
mean, of the available measurements. There is no convincing
evidence to suggest superiority of the mean versus median of
the SSI measurements. However, since the median and IQR are
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robust against non-normal distributed data, they should be pre-
ferred for reporting.
RECOMMENDATION 13
For 2D-SWE a minimum of three measurements should be
obtained; the final result should be expressed as the median
together with the interquartile range (LoE 2b, GoR B) [27,
117]. Strong consensus (18/0/0, 100%)
Reproducibility
Reproducibility in healthy subjects
In three studies, the intraobserver reproducibility of SSI during
the same session was excellent (ICC ranged from 0.92 to 0.95)
[23, 73, 118]. The interobserver agreement on different days
was affected by operator experience and ranged from 0.63 to
0.84 [23, 118].
Reproducibility in patients
The intraobserver reproducibility of 2D-SWE for liver stiffness
assessment in liver fibrosis patients is excellent, with the ICC rang-
ing from 0.90 to 0.95 in published studies [56, 57, 117]. The
intra-subject reproducibility (evaluated over periods of 2 days to
4 weeks) ranges between 0.83 and 0.90 [31]. Interobserver repro-
ducibility on the same day ranges from 0.83 [31] to 0.94 [112].
Intra- and interobserver variance may be inferior to pSWE using
VTQ® [31].
Limitations
Failures
Failure – most often defined as the “inability to obtain an ade-
quate signal for all acquisitions” – occur in up to 10 % of cases
reported in the published series. Common causes of failure are:
depth below 4 – 5 cm [26], poor ultrasound window, reverbera-
tions, pulsatile movement, poor breath hold, large amounts of
ascites [117], intercostal wall thickness ≥ 25mm [119], BMI
≥ 30 kg/m2, histological steatosis and waist circumference
≥ 102 cm [57, 59].
Unreliable assessments
Unreliable measurements are randomly defined across studies
and comparison is limited. Reported predictors of unreliable
results with SSI are similar to those reported for TE and pSWE
[56, 117]. In one study, a lower SD and larger analysis boxes inde-
pendently correlated with correct classifications of severe fibrosis
and cirrhosis [114].
The main factors limiting the applicability of 2D-SWE include
obesity, poor acoustic window or presence of artefacts and inabil-
ity of the subjects to hold their breath [26, 56, 57, 59, 117].
Strain elastography (SE): quasi-static
strain imaging
Procedure
The best B-mode ultrasound image is required since real-time
strain elastography (SE) depends on the quality of the B-mode
images. Acquisition can be improved as follows [32]:
▪ Image the right liver lobe through an intercostal space with the
patient supine and the right arm elevated to widen the inter-
costal space;
▪ Place the transducer lightly on the skin without moving it since
intrinsic, mainly cardiac, movement is often enough to dis-
place the tissue. However, sometimes the operator needs to
induce repeated pressure movements with the probe to create
the necessary stress needed for strain measurements;
▪ Select a region of interest in which B-mode images are free
from interfering structures and artefacts;
▪ Obtain images displaying axial, not lateral or elevational,
movement by pointing the transducer toward the heart;
Have the patient perform a short breath hold to ensure that SE
images are displayed consistently [120].
Analysis region placement and size
Similarly to pSWE and 2D-SWE, the analysis box should be placed
at least 1 cm below the liver capsule [120, 121]. Measurement
should not be performed too deep in the parenchyma as acoustic
shadows, reverberation artefacts, and a lack of sufficient penetra-
tion will generate incorrectly high readings. Some researchers
include the surrounding tissues, such as the subcutaneous and
muscle layers [122, 123]. However, placing the ROI entirely inside
the liver is key to generating uniform images to calculate the liver
fibrosis (LF) index [124]. Large vessels should be avoided by using
a 2.5 × 2.5 cm ROI [120, 125]. Elimination of artefacts requires
attention to technique. Trialling the placement of the transducer
between the ribs will lead to optimal positioning. When an exam-
ination is difficult, attempt another intercostal space, perhaps
selecting one that is softer and with a thinner subcutaneous layer.
Other subcutaneous structures, such as the ribs and lungs, should
not be included in the image. For the analysis, frames with strain
generated in the depth direction with no artefacts should be
selected. Good images may be obtained at the end of diastole
with electrocardiographic gating or at the largest downward
wave.
Evaluation methods
An examiner’s experience influences the outcome of visual assess-
ment. To overcome this, various quantitative and semi-quantita-
tive methods have been developed to assess tissue strain more
objectively. In the research literature “image pattern recognition”
indices obtained by analyzing grayscale, histogram, and binariza-
tion transformations of SE images have been shown to correlate
with liver fibrosis. The strain image is converted to numerical
values, for example using color gradations, with blue being 0 and
red being 255. Some authors have reported that mean strain
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values inversely correlated with liver stiffness and fibrosis in
patients with CHC. On the other hand, the standard deviation
of values of strain, the percentage of area of low strain and its
complexity were positively correlated with liver stiffness and
fibrosis [126].
Scores
Different scores for semi-quantitative interpretation of SE have
been proposed: the German Elasticity Score [121], the Japanese
Elasticity Score [126] and the LF Index [127]. The LF Index (an
algorithm based of nine features evaluated directly by software)
is the only one recommended by the manufacturer [32]. However,
evidence is not sufficient to allow recommendation for clinical
use, at least in European patients [121, 125].
Reproducibility (published literature)
The interobserver consistency among four separate locations in
the liver using a semi-quantitative method was almost perfect
(ICC 0.97) [128]. On the other hand, the intraobserver variability
and intraobserver agreement of SE for the assessment of liver
fibrosis have been criticized in several studies [121, 125], but no
new data are available.
RECOMMENDATION 14
Methods to objectively assess strain are being developed, but
currently cannot be recommended in clinical practice (LoE 5,
GoR D). (Consensus 18/0/0, 100%).
Comparison of results between systems
Introduction
Different US-based SWS technologies are available for the nonin-
vasive assessment of liver fibrosis and the measurements pro-
duced can be slightly to moderately different between systems
from different manufacturers. Even systems that use the same
technique but were developed by different manufacturers can
yield different values due to different and proprietary methods
to measure the SWS.Moreover, the units of measurement may
be meters per second if the speed of the shear wave is expressed
as m/s or kPa if used to calculate the Young’s or shear modulus.
There is another potential difference: it is assumed that the SWS
is independent of the shear wave frequency which is incorrect
since higher frequencies generate shear waves that travel faster.
The ‘dispersion error’ could render results from different studies
incomparable.
Studies on phantoms
The Ultrasound Shear Wave Speed technical committee of the
Radiological Society of North America, Quantitative Imaging
Biomarker Alliance (QIBA) has quantified the differences between
commercially available systems. An inter-laboratory study com-
paring shear wave velocities obtained with four different ma-
chines (Fibroscan, Philips iU22, ACUSON S2000 and Aixplorer)
was conducted [129]. Working on elastic phantoms, a statistically
significant difference in the SWS estimates among systems and
depth of measurement in the phantom was shown, whereas no
statistically significant differences were found among operators
using the same or equivalent systems under the same conditions
[129]. Similar results were obtained using phantoms with viscoe-
lastic properties similar to those observed in normal and fibrotic
liver [130]. The measurements were performed at multiple focal
depths (3.0, 4.5 and 7.0 cm). The deepest focal depth (7.0 cm)
produced the greatest inter-system variability for each phantom
(up to 17.7 %) as evaluated by the interquartile range. Inter-sys-
tem variability was consistent across all phantoms and was not
related to stiffness.
Sources of variability
Several sources of variability are detailed in published studies,
including technical and patient-dependent factors that could
affect comparability between systems.
Technical factors
Measurement depth
As shown by the studies on phantoms [129], the influence of
depth on the estimation of elastic properties is not negligible.
Furthermore, with curved transducers used in liver imaging, the
angle affects the readings, with the best results being achieved
when the ROI is straight ahead. Using VTQ®, it has been shown
that the results with the lowest variability are obtained at a depth
of 4 – 5 cm with a convex transducer (1– 4 MHz; mean push pulse:
2.67MHz) and at a depth of 2 – 3 cm with a linear transducer (4 –
9 MHz; mean push pulse: 4MHz) [131]. The acoustic push pulse is
progressively attenuated as it traverses the tissue. Attenuation is
higher in a stiffer liver. Thus, measurements are more variable in
cirrhotic patients [25].
Frequency of the transducer
In a prospective study on 89 patients with CHC, pSWE (based
on VTQ®) was performed using both available transducers
(4C1 and 9L4) [132]. The linear transducer gave higher values
(1.91 ± 0.87m/s vs. 1.70 ± 0.67m/s). However, the results were
correlated to each other (r = 0.70). Using the same method in a
phantom and a series of eight volunteers, it was found that the
convex transducer showed values that were significantly higher
than those obtained with the linear transducer [131].
Position of the transducer
The highest intra- and interobserver agreement was obtained
for the measurements performed through the intercostal space
rather than the subcostal approach [72, 103, 133].
Operator experience
Methods using pSWE have shown excellent interobserver agree-
ment, with concordance ranging from 0.80 to 0.97 for measure-
ments performed via an intercostal approach, and independent
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of operator experience, suggesting that operators require only a
short period of training to perform reliable LSMs [66, 70, 103,
106]. Using 2D-SWE (SSI) an expert operator had higher reprodu-
cibility of measurements over time than a novice operator [23].
It is suggested that at least 50 supervised 2D-SWE measurements
should be performed by a novice operator in order to obtain con-
sistent measurements.
It was also demonstrated that a novice was able to achieve
reliable results with TE after a single learning session. However,
the success rate progressively increased with the experience of
the operator [16]. On the contrary, it was reported that operator
experience increases the applicability and diagnostic accuracy of
TE [92]. Echosens, the manufacturer of the FibroScan device,
recommends that TE be performed by an experienced operator
(> 100 examinations).
Using liver biopsy as the reference standard, a recent study has
shown that ElastPQ® matched TE for accuracy after the operator
had performed at least 130 examinations [134].
Equipment
Proprietary elastographic technologies generally give different
estimates of the SWS within the same liver. This translates into
the need to define threshold values for fibrotic stages for each
specific equipment model.
Patient-dependent factors
The most important patient-dependent factors for variability
between different elastographic methods are: position (supine
position has been used in most published studies), respiration
phase (deep inspiration affects the measurement; it has been
suggested that a breath hold for a few seconds during quiet
breathing may lead to the best results) [25, 29, 135], non-fasting
state [36– 38], fibrosis stage (lower stages of liver fibrosis seem to
reduce TE reproducibility [94, 136, 137] or the presence of stea-
tosis [52].
Morbid obesity limits the applicability of elastography meth-
ods (TE XL probe, pSWE) and impairs measurement accuracy
[138]. The theoretical possibility that values are different rather
than identical in different parts of the liver, even in the same
region, may also contribute to the variability between different
equipment reported in many studies. Unfortunately, there is
no indication in most studies as to whether the same sampling
position and the same intercostal space were predetermined and
utilized.
Clinical studies
Diagnostic accuracy
The AUROCs of ElastPQ® and VTQ® for predicting the presence
of liver fibrosis were similar (0.85 and 0.82, p = 0.48) [71]. Other
authors compared 2D-SWE (SSI), VTQ®, and TE in 349 consecutive
patients with chronic liver diseases [57]. They found that 2D-SWE,
TE and VTQ® correlated significantly with the histological fibrosis
score (r = 0.79; r = 0.70; r = 0.64 respectively, all p < 0.00 001). The
AUROCs of 2D-SWE, TE, and VTQ® were 0.89, 0.86, and 0.84,
respectively, for the diagnosis of mild fibrosis; 0.88, 0.84, and
0.81, respectively, for the diagnosis of significant fibrosis; 0.93,
0.87, and 0.89, respectively, for the diagnosis of severe fibrosis;
and 0.93, 0.90, and 0.90, respectively, for the diagnosis of cirrho-
sis. 2D-SWE had a higher accuracy than TE for the diagnosis of
severe fibrosis (≥F3) (p = 0.0016), and a higher accuracy than
VTQ® for the diagnosis of significant fibrosis (≥F2) (p = 0.0003).
No significant difference was observed for the diagnosis of mild
fibrosis and cirrhosis. Similar comparison was made in patients
with NAFLD [57]: 2D-SWE had a higher accuracy than VTQ® for
diagnoses of significant fibrosis (≥F2) (p = 0.004).
In a study on 132 patients with chronic liver disease, 2D-SWE,
pSWE (VTQ®) and TE were compared. The reference methods
were liver biopsy for the assessment of liver fibrosis (n = 101) and
magnetic resonance imaging/computed tomography for the
diagnosis of liver cirrhosis (n = 31). No significant difference in
diagnostic accuracy was found between the three elastography
methods for the diagnosis of significant and advanced fibrosis
and liver cirrhosis in the "per protocol" and "intention to diagnose"
cohorts [57].
Several studies have compared the results obtained with
B-mode-based SWE techniques (pSWE, 2D-SWE) to those of TE
and have found that the accuracy of these techniques is similar
to that of TE [59, 139, 140].
Some comparative studies show similar accuracy for different
elastographic systems. Larger prospective studies are necessary
to find if there are differences in accuracy between each different
system for liver stiffness evaluation.
RECOMMENDATION 15
The results with the lowest variability in comparing different
pSWE or 2D-SWE systems were obtained at a depth of 4 –
5 cm from the transducers (with convex transducers) (LoE 4,
GoR C) [131]. Accordingly, this location is recommended if it
is technically suitable. Broad consensus (17/0/1, 94%)
Liver diseases
Introduction
The assessment of fibrosis in chronic liver diseases is pivotal for
prognosis and guiding management, including whether to
commence antiviral treatment. Liver biopsy is considered the
“gold standard” for fibrosis assessment and stage classification
and can also grade necro-inflammatory activity. However, liver
biopsy is limited by its invasiveness, with potential severe compli-
cations in up to 1% of cases, sampling error, since the specimen
represents roughly only 1/50 000 of the liver volume, and the
inter- and intraobserver variability at microscopic evaluation.
Therefore, noninvasive methods for liver fibrosis assessment
including ultrasound elastographic methods have been an intense
field of research [1].
Due to the differences among elastography methods outlined
in previous sections, cut-off values for fibrosis are system-specific
and cannot be equated across machines. Currently, TE is the most
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widely studied method outside of radiology practice, but a consid-
erable amount of evidence regarding other methods has been
published. The results obtained by pSWE (mainly VTQ®) and 2D-
SWE (mainly SSI) show similar accuracy as compared to TE for the
assessment of liver stiffness, with a potentially higher applicability
[59, 112].
It is becoming increasingly clear that the best cut-off values of
the different elastography techniques used to evaluate the
presence and severity of liver fibrosis depend upon the etiology
of the underlying liver disease, and upon the prevalence of the
condition under study in the target population. Although differ-
ent cut-off values have been proposed for cirrhosis according
to etiology (ranging, for instance, from a Young’s modulus of 11
kPa in CHB to 22.6 kPa in alcoholic liver disease), it should be
kept in mind that these cut-off values have been defined in a
single population using ROC curves in order to maximize sensitiv-
ity and specificity – and have not been applied to a validation
cohort. Differences between cut-offs may be simply related to
differences in cirrhosis prevalence and severity in the studied
populations, known as the spectrum bias. Therefore, elastography
values should be interpreted by a liver specialist aware of the
clinical aspects of the liver disease to be assessed and aware of
the peculiarities of elastography in general and each elastography
technique in particular.
Besides increasing evidence regarding liver stiffness measured
by different techniques to detect liver fibrosis and cirrhosis (de-
scribed in detail in the following paragraphs), other new applica-
tions of elastography are being tested in the field of liver diseases.
They include spleen stiffness assessment for portal hypertension
and the evaluation of the stiffness of focal liver lesions to differ-
entiate between benign and malignant nodules. These applica-
tions appear promising, but remain under development and
cannot yet be recommended in clinical practice.
Clinical needs
The ranges for intermediate fibrosis stages (F2-F3) are quite nar-
row, in the order of a Young’s modulus of 2 – 3 kPa (over a total
range spanning 2 to 75 kPa with the TE), so that small differences
in outputs could shift the assessment of patients from one stage
to another [141]. However, in “the real life” situation, attention
should be focused on the patient and what is appropriate from a
clinical point of view. Following the availability of novel antiviral
agents, the European Association for the Study of the Liver
(EASL) together with the Asociación Latinoamericana para el Estu-
dio del Hígado (ALEH) have produced guidelines for the clinical
use of noninvasive tests for the evaluation of liver disease severity
and prognosis [76]. These guidelines have outlined that the two
clinically relevant endpoints in patients with viral hepatitis are
the detection of significant fibrosis (F≥ 2) and the detection
of cirrhosis (F = 4), and the most important endpoint is the detec-
tion of cirrhosis, because it guides treatment (A1 recommenda-
tion). In patients with NAFLD and with chronic liver diseases of
other etiologies, the detection of cirrhosis is also the most impor-
tant clinical endpoint (A1 recommendation).
Clinical decision-making before elastography
Elastography is designed as a noninvasive tool to identify and
stage liver fibrosis, and it should be used in an appropriate man-
ner. Specifically, it should be interpreted along with a diagnostic
workup aimed at identifying the cause of liver disease. This is
important since the interpretation of liver elastography values
depends on the specific clinical scenario, the prevalence of disease
in the population under investigation, the current patient’s
comorbidities and the etiology of the liver disease.
Liver stiffness evaluation is not part of the screening process
and initial evaluation. The main reason for this is that a rational
stepwise approach to the diagnosis and staging of liver disease
should follow the same rationale used for any other disease in
order to optimize the use of resources, limit costs and minimize
the risk of iatrogenic injury. The backbone of any workup is anam-
nesis, physical examination and laboratory tests, followed by the
use of noninvasive diagnostic methods, ideally from less to more
expensive, and following a balanced view of the cost and accuracy
of each for the specific clinical question. The use of invasive meth-
ods, which always imply a certain risk for patients, should be lim-
ited when the previous phases did not provide sufficient informa-
tion. In addition, despite elastography methods being increasingly
used and available in reference centers, they are not yet universal-
ly available and require experience. Therefore, elastography is part
of a clinical decision-making process.
Anamnesis, clinical examination and abdominal ultrasound
examination are recommended prior to elastographic liver evalu-
ation. This strategy detects the presence of ascites, tumoral mas-
ses in the liver, obstruction of the biliary tree, and signs of right
heart dysfunction. Direct liver elastographic evaluation reduces
the time of examination, decreases the cost and can be per-
formed by trained technicians (TE).
Not recommending elastography as a first-line screening
approach for liver disease allows an appropriate diagnostic work-
up in patients without significant fibrosis at elastography. These
patients may have a liver disease prone to progression, despite a
normal elastography measurement.
Screening
According to the WHO principles for screening for disease [142], a
screening test should offer high validity, reliability and acceptance
in the screened population, in addition to a positive balance
between yield and costs and available follow-up services in the
case of a positive test. Thus, SWE may be well suited as a screen-
ing method for asymptomatic liver disease in low prevalence
populations. However, there is insufficient evidence to evaluate
the value of SWE in the general population, in high-risk popula-
tions with intravenous drug use, diabetes mellitus, obesity and/
or alcohol abuse or in migrants from areas with a high prevalence
of HCV and HBV [61, 143 –145].
TE as a screening procedure in a general population > 45 years
has been evaluated in two large studies, with a total of 4700 ap-
parently healthy subjects [61, 143]. One study found that the
presence of diabetes mellitus and obesity was associated with a
Young’s modulus above 8 kPa. However, neither of the studies
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systematically investigated the causes of elevated liver stiffness in
participants with a positive result.
Initial evaluation of chronic liver disease
(prerequisites for SWE)
Current complaints and past medical history
The initial evaluation of a patient with abnormal liver biochemical
and/or function tests includes knowledge (anamnesis) of current
complaints, obtaining a past medical history to identify potential
risk factors for liver disease and performing a physical examina-
tion to look for clues to the etiology and for signs of chronic liver
disease. Elastography should not be performed without the
knowledge of current complaints, past medical history and basic
laboratory testing
Conventional ultrasound
Conventional ultrasound examination could be part of the initial
evaluation [146], especially if the equipment is located within
the clinic. Conventional B-mode ultrasound can be used not only
to detect the classic features of established cirrhosis but also
to determine the presence of biliary dilation indicating extrahepa-
tic cholestasis and of signs of cardiac failure or hepatic vein
disease, which are conditions limiting the accuracy of elastogra-
phy. B-mode US screening for focal liver lesions, splenic size,
venous collaterals, ascites and other signs of portal hypertension
can also be performed. Ascites precludes the use of TE elastogra-
phy. Knowledge of conventional B-mode ultrasound findings is
mandatory before strain and SWE elastographic examination, or
at least affects interpretation of the elastography results. Doppler
ultrasound is a basic tool for the optimization of B-mode ultra-
sound and the exclusion of vascular liver disease and is helpful for
determining complications of chronic liver disease, e. g., portal
hypertension.
In conclusion, in patients with liver disease of unclear etiology,
elastography should not be interpreted without a complete ultra-
sound assessment of the upper abdomen (B-mode and Doppler
ultrasound).
Chronic hepatitis C (CHC)
Fibrosis staging
Transient elastography
In patients with CHC, TE can differentiate absent and mild fibrosis
from significant fibrosis and cirrhosis, but is not accurate enough
to distinguish between separate stages of fibrosis (F1 – F4) [147 –
149]. A Young’s modulus greater than 6.8 – 7.6 kPa indicates a
high probability of significant fibrosis (F ≥ 2) on biopsy. However,
optimal cut-off values vary considerably depending on fibrosis
prevalence and may range between 5.2 kPa – 9.5 kPa as indicated
in the clinical practice guidelines of the EASL [76]. Accordingly,
the optimal cut-off values for predicting cirrhosis (F = 4) range
between 11 and 15 kPa [76]. Therefore, the local fibrosis preval-
ence and the diagnostic aim (sensitive screening vs. secure exclu-
sion strategies) must be considered when adapting cut-off values
for clinical use. It should be emphasized that TE gives the best
diagnostic performance in the context of cirrhosis diagnosis, and
for this purpose it is better at ruling out than at ruling in cirrhosis.
In CHC patients with HIV co-infection, TE can be used with
similar diagnostic accuracy as compared to HCV infection alone
for fibrosis and cirrhosis detection [150]. TE can also be helpful in
liver transplant recipients for the staging of recurrent fibrosis and
cirrhosis [151].
The use of TE for the diagnosis of cirrhosis and the estimation
of fibrosis severity in CHC has been endorsed in the recommenda-
tions for the management of viral hepatitis by the EASL and the
ALEH, ideally in combination with an alternative and unrelated
noninvasive approach such as laboratory tests/serum markers of
fibrosis [152]. In the case of TE failure or inconclusive noninvasive
test results, biopsy is still recommended when fibrosis staging is
relevant for clinical decisions, although a preliminary attempt
with an alternative SWE method could be considered.
RECOMMENDATION 16
TE can be used as the first-line assessment for the severity of
liver fibrosis in patients with chronic viral hepatitis C. It per-
forms best with regard to the ruling out of cirrhosis (LoE 1b,
GoR A) [25, 150, 152]. Broad consensus (17/0/1, 94%)
Point shear wave elastography (pSWE)
As with TE, VTQ® SWS quantification has been studied extensively
in patients with CHC. Cut-offs of 1.21 – 1.34m/s predict signifi-
cant fibrosis (F ≥ 2) (AUROC 0.85 – 0.89), while VTQ® cut-offs
between 1.55 and 2m/s (AUROC 0.89 – 0.93) predict cirrhosis
[104, 153]. The diagnostic performance of VTQ® is comparable
to TE [154] with high accuracy for predicting significant (F ≥ 2,
AUROC 0.87) and severe fibrosis (F ≥ 3, AUROC 0.91) as well as
cirrhosis (AUROC 0.93) [155]. However, discordance (> one fibro-
sis stage) between VTQ® and histology occurred in > 30 % in a
study including 106 patients infected with HCV. The discordance
was associated with female gender and a high interquartile range
(IQR/M ≥ 30%) of Young’s modulus [107]. Therefore, pSWE results
require cautious interpretation. Evidence regarding ElastPQ® is
limited [70, 156]. The results in the pilot study [70] for fibrosis
staging are similar to those reported for VTQ®, but more data
are needed. Fibrosis biomarkers may help to clarify indistinct
cases [157].
RECOMMENDATION 17
pSWE as demonstrated with VTQ® can be used as the first-line
assessment for the severity of liver fibrosis in patients with
chronic viral hepatitis C. It performs best with regard to the
ruling out of cirrhosis (LoE 2a, GoR B) [155]. Broad consensus
(17/0/1, 94%)
2D shear wave elastography (2D-SWE)
2D-SWE using SSI was reported in several studies in patients with
CHC [139, 158]. Diagnostic accuracy was high for the detection of
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significant and advanced fibrosis and cirrhosis (AUC> 0.90).
In these studies the diagnostic performance for 2D-SWE was
better than for TE [139, 159] and serum fibrosis markers (FIB-4
index, APRI and Forns' index) [159]. In one study including 102 ob-
ese CHC patients, 2D-SWE had excellent diagnostic accuracy for
the detection of severe fibrosis and cirrhosis (AUROC > 0.90 for
both) [91].
RECOMMENDATION 18
2D-SWE as demonstrated with SSI can be used as a first-line
assessment for the severity of liver fibrosis in patients with
chronic viral hepatitis C. It performs best with regard to the
ruling out of cirrhosis (LoE 1b, GoR A) [139, 158, 159]. Broad
consensus (17/0/1, 94%)
Strain Elastography
Among the manufacturers, only Hitachi SE has been evaluated
for the assessment of fibrosis in liver disease and in viral hepatitis.
Different scores for semi-quantitative interpretation of SE in the
liver have been proposed [1]. While the method produced promis-
ing results for the prediction of liver fibrosis in Asian patients, its
performance was inferior to TE in European patients [121, 125].
New data on this technique are lacking.
Prediction of hepatic complications
Growing evidence supports the use of TE for risk stratification and
the prediction of clinical endpoints. Liver stiffness predicts 5-year
mortality with better accuracy than histological fibrosis staging
(METAVIR) for HCV mono-infected (TE > 9.5 kPa) [160] and HIV
co-infected patients (TE > 9.0 kPa) [161]. Furthermore, an elevat-
ed Young’s modulus indicates an increased risk of HCC develop-
ment (TE > 10 kPa) [162], hepatic decompensation and variceal
bleeding [163]. Especially for patients with an established diagno-
sis of cirrhosis, TE can be used for grouping patients into different
risk classes [162]. The combination of liver stiffness (Young’s
modulus of > 14 kPa) with platelet count (< 141 × 103/μL) and
response to antiviral treatment may increase the predictive value
of TE for HCC development [164]. In patients with compensated
liver cirrhosis, liver stiffness helps to identify patients with portal
hypertension (see section recommendations on portal hyperten-
sion). Data regarding firm endpoint prediction using pSWE and
2D-SWE are lacking and no evidence-based recommendation can
be specified. Two groups evaluated the predictive value of TE in
transplant patients with a recurrence of HCV infection [165,
166]. A Young’s modulus > 8.7 kPa at 12 months after liver trans-
plantation was associated with a significantly reduced five-year
graft and cumulative patient survival [165].
Role of elastography in the setting of anti-HCV treatments
Role of SWE to identify patients to be treated
In the absence of universal access to direct-acting antiviral agents
(DAA) as a consequence of high cost, different countries have
implemented strategies to prioritize patients for treatment. TE
is used as the first-line investigation for the prioritization of HCV
patients for DAA (e. g. Young’s modulus values ≥ 7.1 kPa are
considered equivalent to fibrosis ≥F2, and values ≥ 9.5 kPa are
considered equivalent to fibrosis ≥F3). In countries using interfer-
on-based strategies, TE can help to identify patients with cirrhosis
who have a lower likelihood of achieving a sustained virological
response (SVR: undetectable HCV-RNA, 24 weeks after comple-
tion of antiviral therapy).
Role of SWE during treatment (monitoring)
Limited evidence in the setting of interferon-based therapy post-
ulated that increasing liver stiffness as measured by TE during the
treatment period might indicate a reduced possibility of achieving
a sustained virological response [167, 168]. Data in patients
undergoing IFN-free antiviral therapies suggest that liver stiffness
rapidly declines during treatment, even in patients with advanced
fibrosis and cirrhosis. This decline appears to reflect the reduction
in liver inflammation, restoration of liver function and the
decrease in portal pressure, like an effect of HCV eradication
[169, 170].
Role of SWE after treatment (monitoring in follow-up)
Data regarding the usefulness of liver stiffness monitoring during
antiviral therapy are scant. In the largest prospective study pub-
lished (n = 91), a significant liver stiffness decrease was observed
during therapy with peg-interferon and ribavirin; the decrease in
liver stiffness continued after treatment only in patients who
achieved SVR [171]. In the era of DAAs, it is important to remark
that after successful HCV eradication, the use of pre-treatment
cut-off values can impair the accuracy of TE [172, 173], and it
might lead to erroneous conclusions if the SVR status is not care-
fully taken into account [170]. Several studies have evaluated
the use of VTQ® for monitoring IFN-based antiviral therapy in
HCV patients: SWE decrease or increase reflects response or no
response to treatment, respectively [174 – 176]. For IFN-free anti-
viral therapies, no data are available.
The monitoring of cirrhotic patients after SVR will become the
new standard in the era of DAAs. Although it is tempting to use
SWE in this setting to observe the dynamics of liver stiffness over
time, no recommendation can be made at this stage on cut-offs
and the time interval to identify cirrhosis regression.
RECOMMENDATION 19
SWE is not recommended to monitor fibrosis changes during
anti-HCV treatment (LoE 3, GOR D) [172, 173]. Strong con-
sensus (18/0/0, 100%)
RECOMMENDATION 20
LSM changes after successful anti-HCV treatment should not
affect the management strategy (e. g. surveillance for HCC
occurrence in patients at risk) (LoE 3, GOR D) [76]. Broad con-
sensus (16/0/1, 94%)
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Chronic Hepatitis B (CHB)
Introduction
A large amount of evidence regarding elastography in CHB is avail-
able. There are > 50 published studies. The majority of them use
TE but also validate the elastographic methods of pSWE and
2D-SWE.
Fibrosis staging
The most important goal of noninvasive diagnostic tools is diag-
nosis of compensated cirrhosis that would benefit from treatment
regardless of the transaminase level [177].
Transient elastography
Transient elastography is the most validated elastographic meth-
od for staging CHB and has similar accuracy in this clinical sce-
nario compared to CHC [76]. Three meta-analyses confirmed the
good performance of TE in CHB staging [178 – 180]. Despite LSMs
showing a substantial overlap among adjacent stages of fibrosis
(particularly at lower fibrosis stages), LSM may effectively identify
patients with ≥F2 and F4. Recent publications confirmed previous
evidence, suggesting that the AUROCs for ≥F2 vary between 0.80
and 0.90 [181, 182] with Young’s modulus cut-off values between
6.6 kPa and 8.8 kPa [182, 183]. Regarding the identification of cir-
rhosis (F4), recent data confirm previous evidence, with AUROCs
ranging between 0.81 and 0.97 [182] and cut-off values between
9.4 and 13.4 kPa [184, 185]. A recent meta-analysis suggested
that a value > 11.7 kPa should raise suspicion of cirrhosis [178]. It
has been suggested that LSM cut-offs should be adapted to trans-
aminase levels [185] since transaminase levels tend to influence
LSM in CHB, and hepatitis flares are often observed in CHB. How-
ever, recent studies showed that ALT-adapted cut-offs do not in-
fluence TE diagnostic performance [186] and that the only vari-
able associated with overestimation of F4 stage in CHB is
moderate/severe necro-inflammatory activity without any direct
correlation with transaminase level [187]. Interestingly, a Young’s
modulus of < 5 kPa in patients with normal ALT and low serum
HBV DNA levels (< 2000 IU/ml) characterize inactive HBV carriers
[188, 189]. TE can be used to rule out significant fibrosis and cir-
rhosis in HBV inactive carriers, which is the best indication for TE in
HBV.
RECOMMENDATION 21
TE is useful in patients with CHB to identify those with cirrho-
sis. Concomitant assessment of transaminases is required to
exclude flare up (elevation > 5 times upper limit of normal).
(LoE 1b, GoR A) [178 – 180]. Broad consensus (17/1/0, 94%)
RECOMMENDATION 22
TE is useful in inactive HBV carriers to rule out fibrosis (LoE 2,
GOR B) [188, 189]. Strong consensus (18/0/0, 100%)
Point shear wave elastography (pSWE)
VTQ® has the advantage of a lower failure rate and has a similar
diagnostic performance as TE. The discriminative ability for
staging fibrosis in CHB is good, with AUROCs for ≥F2 and F4 of
0.76 – 0.91 [184, 190] and 0.72 – 0.97 [155, 184], respectively.
These findings were confirmed in a meta-analysis that included
patients with several etiologies of liver disease. The analysis of
data of patients with CHB showed an AUROC for ≥F2 of 0.88 and
the best cut-off was 1.35m/s and the AUROC for F4 was 0.93 and
the best cut-off was 1.87m/s [191, 192]. There is limited data
about other pSWE methods. ElastPQ® has been used for staging
CHB patients in four studies, with good performance for staging
liver fibrosis. Further validation is required [106, 192 – 194].
2D shear wave elastography (2D-SWE)
Recently, 2D-SWE (SSI) was tested in patients with CHB and
proved to have a lower failure rate than TE and at least similar
performance for fibrosis staging [195]. The AUROC for ≥F2 varies
between 0.85 and 0.91 [58, 196], with Young’s modulus cut-offs
between 7.1 and 8.0 kPa [195, 196], while the AUROC for F4
varies between 0.92 and 0.98 [195, 197], with optimal cut-offs
between 10.1 and 11.7 kPa [58, 195]. The best indications of 2D-
SWE in HBV are inactive carriers to rule out significant fibrosis and
cirrhosis diagnosis.
RECOMMENDATION 23
pSWE as demonstrated with VTQ® is useful in patients with
CHB to identify those with cirrhosis (LoE 2a, GoR B) [191].
Strong consensus (18/0/0, 100%)
RECOMMENDATION 24
2D-SWE as demonstrated with SSI is useful in patients with
CHB to identify those with cirrhosis (LoE 3a, GoR C) [196,
197]. Broad consensus (17/0/1, 94%)
Monitoring (evaluation of) response to treatment
Under nucleoside/nucleotide analogs, liver stiffness measured by
TE significantly decreases regardless of the baseline values of ALT
[198, 199]. The only factors associated with decline of LSM are
higher baseline LSM and HBV DNA levels [198]. The diagnostic
accuracy and thresholds of liver stiffness using TE may differ in
untreated and treated patients with chronic hepatitis B and C.
This aspect should be taken into account when interpreting the
results of elastography. Moreover, even if liver stiffness declines
with antiviral treatment, it is unknown if this reflects disease
regression and LSM changes should not affect management.
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RECOMMENDATION 25
LSM changes under HBV treatment should not affect the
management strategy (e. g. surveillance for HCC occurrence
in patients at risk) (LoE 2b, GOR B) [198, 199]. Strong consen-
sus (16/0/0, 100%)
Prognostic relevance
Baseline LSM by TE has modest prognostic relevance with an AUR-
OC between 0.70 and 0.73 for liver-related events [200, 201],
which may be increased by adding spleen diameter and platelet
count as a prediction model called LSPS (= LSM × spleen diame-
ter/platelet count) up to a level of 0.83 [202]. TE is a good prog-
nostic marker for HCC development that may occur without
cirrhosis. A Young’s modulus of > 8 kPa might be a value indicating
the need to start screening for HCC, even if a complete virological
response was achieved [203, 204]. The risk of HCC is even higher
if the Young’s modulus by TE is > 12 – 13 kPa, which also implies
an increased risk of decompensation [181, 203 – 205].
Non-alcoholic fatty liver disease (NAFLD)
In NAFLD patients, noninvasive markers should aim at the follow-
ing: a) identify the risk of NAFLD/NASH among individuals with
metabolic syndrome; b) identify those with a worse prognosis; c)
monitor disease progression; d) predict response to treatment.
Fibrosis staging
Transient elastography
A particular problem in NAFLD patients is the failure rate of elasto-
graphy. Different studies report increased failure rates owing to
increased body mass index (BMI > 30 kg/m²) or waist circumfer-
ence, which may interfere with the transmission of the push
impulses and the tracking ultrasound, thus preventing correct
estimation of liver stiffness. A second issue in NAFLD patients is
that two probes are available (M and XL probes), with the latter
being dedicated to use in overweight subjects. Comparing the
diagnostic performance of the two probes (M and XL probes),
the XL probe obtains more reliable results than the M probe in
obese patients. The main limiting factors for the XL probe are a
skin-to-liver capsule distance > 3.4 cm and extreme obesity (BMI
> 40 kg/m²). The third issue is that F3-F4 fibrosis is the most
important prognostic factor for liver-related outcomes and mor-
tality in NAFLD patients.
TE performance is better for cirrhosis than for significant fibro-
sis [206, 207]. TE has a higher rate of false-positive than false-neg-
ative results and a higher negative predictive value (NPV) than
positive predictive value (PPV). Therefore, the ability to diagnose
bridging fibrosis or cirrhosis is insufficient for clinical decision-
making [208, 209]. A systematic review of TE in patients with
NAFLD involved 9 studies and 1047 patients [210]. TE was excel-
lent in diagnosing F3 fibrosis (85% sensitivity, 82% specificity) and
cirrhosis (92% sensitivity, 92% specificity), but had only moderate
accuracy for F2 fibrosis (79% sensitivity, 75% specificity).
With the M probe, patients with steatosis > 66% at liver biopsy
had higher LSM values, which led to higher false-positive LSM
results [52]. Thus, in obese patients with a high degree of steato-
sis, TE (using the M probe) may be less accurate in diagnosing
severe fibrosis in NAFLD, and additional evaluation may be
warranted to avoid overestimation of fibrosis. However, additional
studies on the effects of steatosis on LSM measured with an XL
probe are needed. The XL probe produces lower stiffness values
than the M probe. Different cut-offs should be used [85]. With
the M probe, at a Young’s modulus cut-off value of 7.9 kPa, the
sensitivity, specificity, PPV and NPV for F3 or greater disease are
91%, 75%, 52%, and 97%, respectively [55].
In NAFLD patients, the best cut-off for F3 or greater disease
is 7.2 kPa. With this cut-off, the NPV to exclude F3 or greater
disease is 89 % (95% CI 84 – 95%). Cut-off values of 5.7 kPa and
9.3 kPa have 90 % sensitivity and specificity to rule out and rule
in F3 disease, respectively [55].
RECOMMENDATION 26
TE can be used to exclude cirrhosis in NAFLD patients (LoE 2a,
GoR B) [76, 210]. Broad consensus (13/0/3, 81%)
Point shear wave elastography (pSWE)
A systematic review of 7 studies for a total of 723 patients who
underwent SWS measurements with VTQ® technique to evaluate
the diagnostic efficacy of pSWE in patients with NAFLD was
recently published [211]. The summary sensitivity was 80.2 % for
detecting significant fibrosis, which is not an appropriate
endpoint.
2D shear wave elastography (2D-SWE)
There are only two studies that evaluate the performance of
2D-SWE (SSI) [57, 212]. The results are too limited to make
recommendations.
Comparison of different elastographic methods for NAFLD
One study recently compared TE (using the M probe), pSWE
(VTQ®) and 2D-SWE (SSI) in 291 patients with NAFLD enrolled in
two different hospitals [57]. All methods showed AUROCs ≥ 0.84
for severe fibrosis and cirrhosis and had a similar performance
for the diagnosis of these endpoints. The diagnostic performance
of 2D-SWE was superior to that of VTQ® for the diagnosis of
significant fibrosis.
Follow-up of patients
Monitoring of the progression of fibrosis is also necessary in the
follow-up of these patients. Patients who achieved a ≥ 5% weight
loss at the 6-month follow-up showed a decrease in LSM by TE,
independent of the changes in aminotransferase levels [208].
No data are available for pSWE and 2D-SWE.
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Prediction of liver-related complications
A recent study supports the use of TE for risk stratification and
prediction of clinical endpoints [213]. For pSWE and 2D-SWE
data on this aspect are lacking and no evidence-based recommen-
dation can be given.
Alcoholic liver disease (ALD)
Fibrosis staging
Transient elastography in patients with prior or current chronic
alcohol overuse can distinguish absent and mild fibrosis (F0 – 1)
from severe fibrosis and cirrhosis, but similar to other etiologies,
there is no evidence to suggest that it can differentiate absent
and mild fibrosis from significant fibrosis. [214] Additionally, in
the eight published single etiology studies on TE for staging liver
fibrosis, there is no consensus regarding optimal Young’s modulus
cut-off values for significant fibrosis (≥F2), severe fibrosis (≥F3) or
cirrhosis (= F4) [49, 56, 215 – 220]. The optimal cut-off values
range from 7.8 [216] to 9.6 [56] kPa for significant fibrosis, from
8.0 [49] to 17.0 [218] kPa for severe fibrosis and from 12.5 [49] to
22.7 [215] kPa for cirrhosis. The considerable discrepancy
between cut-off values in individual studies is likely a conse-
quence of differences in fibrosis stage prevalence with overrepre-
sentation of cirrhotic patients, place of recruitment, and whether
patients with alcoholic hepatitis or decompensated disease were
excluded.
TE is more suited to rule out than rule in cirrhosis. At a Young’s
modulus of 12.5 kPa, TE may rule out cirrhosis with a negative
likelihood ratio of 0.07 if the disease prevalence is 50% or lower.
[214].
RECOMMENDATION 27
TE can be used to exclude cirrhosis in patients with alcoholic
liver disease, provided that acute alcoholic hepatitis is not
present (LoE 2b, GoR B) [56, 214, 219, 220]. Strong consensus
(15/0/0, 100%)
Prognostication of alcoholic liver cirrhosis
There is scant evidence to suggest a role for ultrasound elastogra-
phy for determining the prognosis and for the monitoring of
patients with alcoholic liver disease [221], or for TE to predict
esophageal varices [222] and the hepatic venous pressure gradi-
ent in patients with alcoholic cirrhosis [221].
Timing of liver stiffness measurements with regard
to alcohol abstinence
In patients undergoing alcohol detoxification, 0.5 to 4 weeks of
abstinence causes a clinically significant decrease in TE [49 – 51,
223]. However, the decrease is associated with a normalization
of transaminases, bilirubin, alkaline phosphatase and/or gamma-
glutamyltransferase. It is, therefore, unclear whether alcohol
alone or alcohol-induced hepatitis and cholangiocyte damage
cause the increase in liver stiffness. [220]. One study suggests
that TE is accurate for staging in patients with ongoing alcohol
abuse but normal gamma-glutamyltransferase [56], while
another study suggests that AUC for the diagnosis of cirrhosis in
alcoholic patients diminishes when AST is above 100 – 150 U/L
[220].
Screening the general population or high-risk groups
in primary care
Ultrasound elastography for systematic screening of high-risk
populations in primary care for alcoholic liver disease was
performed in one study. TE was offered to primary care patients
with an AST:ALT ratio ≥ 0.8 [224]. However, This study did not in-
clude biopsy confirmation in patients with elevated TE. In a diag-
nostic study, TE had excellent diagnostic accuracy for significant
fibrosis and cirrhosis in a subgroup of 71 patients recruited from
primary alcohol rehabilitation centers [56].
With a prevalence of cirrhosis of 2 – 4% in a background popu-
lation of at-risk individuals [225], the PPV of TE should be consid-
ered low regardless of cut-off values.
Point shear wave elastography (pSWE) and 2D-SWE
There is only one study to support the use of 2D-SWE (SSI) for
assessing alcoholic liver fibrosis [56]. There are three small studies
on the use of pSWE [226 – 228], two of which report diagnostic
accuracies and test probabilities. The results are consistent
regarding diagnostic accuracy, which suggests that VTQ® may be
used to rule out severe fibrosis and cirrhosis. The results regarding
cut-off values are, however, inconsistent. Therefore, there is insuf-
ficient evidence to make recommendations for using VTQ® to
distinguish absent and mild fibrosis (F0 – 1) from significant or
severe fibrosis and cirrhosis. Thus, there is still insufficient evi-
dence to evaluate the role of pSWE or 2D-SWE in alcoholic liver
disease.
Cholestatic liver disease and autoimmune hepatitis (AIH)
Risk stratification is a major need in patients with chronic chole-
static diseases in order to allow personalized management and
the selection of candidates for clinical trials of new drugs. Studies
of liver stiffness as a surrogate of liver fibrosis and prognosis
focusing on cholestatic liver disease (primary biliary cholangitis-
PBC, primary sclerosing cholangitis-PSC) or AIH are scarce. Most
available data focus on TE [229 – 231].
Transient elastography
Transient elastography is currently considered one of the best sur-
rogates of fibrosis in PBC. High baseline or increasing values over
time indicate a worse outcome in this population [191, 229]. Liver
stiffness was investigated in 73 patients with PSC, regularly under-
going clinical and elastographic follow-up [232]. LSMs were
able to differentiate severe vs. non-severe fibrosis with a high dis-
criminative accuracy for cirrhosis (AUROC 0.88). There was high
reproducibility between two operators. Higher baseline LSM and
an increase of LSM over time were associated with adverse out-
come such as death, liver transplantation, ascites, hepatic ence-
phalopathy, gastrointestinal bleeding, or HCC [232]. Dilatation of
the intrahepatic biliary system due to a dominant stricture should
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be excluded in PSC before interpreting the LSMs. Cholestasis
increases liver stiffness independent of liver fibrosis.
Data regarding the pediatric population with biliary atresia
suggest that liver (and spleen) elastography could be a valuable
tool to predict outcomes before surgery, and might be used after
the Kasai operation to monitor liver disease and portal hyperten-
sion [233].
Due to the limited evidence, no recommendation can be given.
Point shear wave elastography (pSWE)
VTQ® was initially performed in 9 patients with AIH, PBC and PSC
having higher shear wave velocities than healthy volunteers [234].
In total two studies dealt with VTQ® in AIH and primary biliary
cholangitis. In 15 patients with treated AIH, VTQ® could differ-
entiate between the absence of fibrosis and significant fibrosis
[235]. SWS assessed by VTQ® showed good diagnostic accuracy
for detecting cirrhosis (AUROC 0.91) in 61 patients with primary
biliary cholangitis [236].
2D shear wave elastography (2D-SWE)
Data regarding 2D-SWE in AIH, PBC and PSC are not available.
Liver stiffness assessment helped in differentiating between bili-
ary atresia and neonatal hepatitis in one study [237].
Due to the paucity of data, no recommendation can be given.
Portal hypertension
Transient elastography
In patients with compensated advanced chronic liver disease/
cirrhosis LSM correlates with the hepatic venous pressure gradient
(HVPG). Even though the correlation between the two does not
allow for an accurate estimate of the exact HVPG value (range:
0.59 – 0.70), the discriminative ability of liver stiffness for the
presence of clinically significant portal hypertension (CSPH,
defined as HVPG ≥ 10mmHg, threshold for the appearance of
complications) is very high, with a summary AUROC of 0.93 in a
recent meta-analysis [238]. However, it should be emphasized
that most of the patients included in the studies concerning
HVPG had viral or alcoholic cirrhosis, and evidence regarding
other etiologies is limited. In viral cirrhosis, Young’s modulus
values of > 20 – 25 kPa are highly specific for CSPH, and values of
> 21 kPa predict the onset of a first clinical decompensation with
an accuracy similar to that of HVPG > 10mmHg [239].
RECOMMENDATION 28
LSM with TE is useful to identify patients with a high likelihood
of having clinically significant portal hypertension (HVPG
≥ 10mmHg) (LoE 2b, GoR B) [238, 239]. Strong consensus
(15/0/0, 100%)
The accuracy of LSM in predicting the presence and size of gastro-
esophageal varices has been the subject of several studies.
Despite the fact that it is currently the best single noninvasive
predictor in this field with summary AUROCs of 0.84 for esopha-
geal varices (EV) and 0.78 for large EV in a recent meta-analysis
[238], the cut-offs vary widely among the studies, and the accura-
cy is not sufficient to replace endoscopy. The accuracy of LSM for
the diagnosis of CSPH and varices improves if it is combined with
platelet count and spleen size [240, 241]. Recent data indicates
that if a combination of a Young’s modulus value of < 20 kPa and
a platelet count of > 150 G/L is used, varices needing treatment
can be ruled out with a high accuracy (< 5 % of patients missed)
[242, 243], and endoscopy can be safely avoided [244].
Point shear wave elastography (pSWE)
Point SWE (VTQ®) has been used in three studies addressing the
diagnosis of CSPH [245 – 247], and showed excellent applicability
and very good diagnostic accuracy (AUROC 0.82 – 0.90). VTQ®
has been used in a few studies addressing the diagnosis and sever-
ity of esophageal varices. SWS was higher in patients with esoph-
ageal varices of any size, and was even higher in patients with
large varices [245, 246]. However, reliable cut-offs are not avail-
able yet. No strong recommendation regarding the cut-offs to be
used can be made due to the limited evidence.
2 D shear wave elastography (2D-SWE)
2D-SWE (SSI) has been tested for the diagnosis of CSPH in 4 stud-
ies and a further small series [27, 248 – 251]. The accuracy of the
method was reliable in all of the published studies (AUROC 0.80 –
0.92).
Two studies performed a head-to-head comparison between
LSM by TE and 2D-SWE [27, 248]. TE was less applicable, and
both techniques showed similar accuracy for the diagnosis of
CSPH.
LSM by 2D-SWE is higher in patients with esophageal varices of
any size and is further increased in patients with large varices.
However, reliable cut-offs are not available yet. No strong recom-
mendation regarding the cut-offs for 2D-SWE can be given, and
further evidence is needed.
RECOMMENDATION 29
Liver stiffness using TE combined with platelet count is useful
to rule out varices requiring treatment (LoE 2b, GoR B) [244].
Although preliminary results are encouraging, there is insuf-
ficient evidence to recommend pSWE and 2D-SWE in this
setting. Broad consensus (13/0/1, 93%)
Reimbursement
Social health care systems and noninvasive
liver fibrosis
The data on the cost-effectiveness of liver elastography are
limited to TE, are mainly derived from UK and Canadian health
care systems and depend on local health care economic condi-
tions. Although TE is generally accepted as a noninvasive alterna-
tive for the staging of liver fibrosis, which helps to avoid a liver
biopsy [252], it does not represent the most effective approach
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with respect to resources in common clinical scenarios [253]. TE is
considered cost-effective for annual cirrhosis screening in patients
infected with HCV [254], with the most cost-effective treatment
scenario for patients infected with HCV not depending on the fi-
brosis category (“treating all”) [253]. However, in countries that
cannot afford the “treating all” scenario, TE is the accepted meth-
od to identify patients deserving access to treatment based on the
greater severity of fibrosis, making it competitive in cost-effec-
tiveness in comparison to biopsy to screen large populations of
patients. Inaccurate noninvasive fibrosis staging may limit the
cost-saving value of elastography [255]. Weighing the diagnostic
limitations and costs of elastography against laboratory-based fi-
brosis scores, widely available and cheap scoring systems (e. g.
AST-to-platelet ratio index) are the recommended method in re-
gions with limited health care resources [256]. Considering the
emerging prevalence of non-alcoholic fatty liver disease (NAFLD)
in industrialized countries, TE can represent a cost-effective ap-
proach for the screening of patients at risk for disease
progression and complications [257, 258]. However, a formal
study assessing hard outcomes such as survival, hospitalization
rates, etc., has not been performed recently and is unlikely to be
performed given the vast number of patients required.
Current reimbursement in European countries
Reimbursement is often limited to conventional ultrasound,
which includes shear wave-based liver stiffness assessment. For
example, no reimbursement is available within the compulsory
health insurance for TE (Fibroscan®) in Germany. In private prac-
tice, 50 – 150 € is usually charged for a Fibroscan® examination.
In many other European countries, no specific reimbursement
code is established. Where ultrasound elastography is reimbursed
(e. g. some regions in Italy), it is accepted under the code of liver
ultrasonography. However, the same exam cannot be reimbursed
twice on the same day. Therefore, conventional ultrasonography
and ultrasound elastography of the liver cannot be reimbursed
together at the same appointment, thus limiting the cost-effec-
tiveness of the technique. In Romania, TE is reimbursed in the
daily hospitalization system with the possibility for future reim-
bursement of pSWE and 2D-SWE. In private practice, the cost of
TE is between 50 and 120 €.
Outlook: what should be done?
One future possibility in liver elastography is to compare the accu-
racy of different technologies (TE, pSWE and 2D-SWE) in a large
cohort of patients with division of the etiologies of liver diseases.
Probably, as indicated by earlier comparative studies, we will have
some results showing the superiority of new technologies in com-
parison with established ones (point or 2D-SWE vs TE). Robust
cut-off values must be established for each of the different
systems and diseases. The combination of elastographic methods
using ultrasound with biological tests may improve the accuracy
of the evaluation of the patients.
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This is to clarify that in the published EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography,
Update 2017 (Long Version) in Figure 1 (“The types of elastography described in this paper”) the availability of Easaote SpA point shear
wave technology (pSWE) was not mentioned. Herewith we present the corrected figure.
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